5-membered heteroaryl derivatives containing at least one N, and pharmaceutical compositions containing the same as an active ingredient for use in the prevention or treatment of mental disorders

A 5-membered heteroaryl derivative with N acts as a triple reuptake inhibitor for serotonin, norepinephrine, and dopamine, addressing the lack of specificity in current psychiatric drugs by modulating multiple neurotransmitters, enhancing treatment efficacy for mental disorders.

JP7580849B2Active Publication Date: 2024-11-12TRINUERO
View PDF 9 Cites 0 Cited by

Patent Information

Application Number
JP2023517643
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2020-05-29
Filing Date
2021-05-25
Publication Date
2024-11-12
Estimated Expiration
2041-05-25

AI Technical Summary

Technical Problem

Current psychiatric drugs lack specificity in targeting multiple neurotransmitters, leading to therapeutic inefficacy and side effects due to their selective action on a single nervous system, necessitating the development of drugs that can modulate multiple targets with differential selectivity.

Method used

A 5-membered heteroaryl derivative containing at least one N is developed to act as a triple reuptake inhibitor for serotonin, norepinephrine, and dopamine, providing a pharmaceutical composition for the prevention or treatment of mental disorders.

Benefits of technology

The compound effectively inhibits the reuptake of serotonin, norepinephrine, and dopamine, offering a versatile treatment option for various mental disorders with reduced side effects and improved therapeutic efficacy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007580849000001
    Figure 0007580849000001
  • Figure 0007580849000002
    Figure 0007580849000002
  • Figure 0007580849000003
    Figure 0007580849000003
Patent Text Reader

Abstract

The present invention relates to N-containing five-membered heteroaryl derivatives and pharmaceutical compositions containing the same as active ingredients for use in the prevention or treatment of mental disorders. The derivatives have excellent triple reuptake inhibitory effects on serotonin, norepinephrine, and dopamine, and are therefore useful in the treatment of mental disorders.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a 5-membered heteroaryl derivative containing at least one N, and a pharmaceutical composition containing the same as an active ingredient for use in the prevention or treatment of a mental disorder. [Background technology]

[0002] Mental disorders are pathological abnormalities in the brain that are characterized by identifiable symptoms that result in abnormalities in cognition, emotion, mood, and affect. Representative mental disorders include attention deficit hyperactivity disorder (ADHD), panic disorder, bipolar disorder, depression, schizophrenia, eating disorders, dissociative disorders, and post-traumatic stress disorder, and these disorders are characterized by various functional disorders, severity of symptoms, and duration. Factors that cause mental disorders include: 1) brain secretion disorders due to excess or deficiency of neurotransmitters that affect brain nerve function, 2) brain damage or degeneration of brain function, 3) abnormal secretion of hormones, and 4) stress.

[0003] The numerous nerve cells that make up the brain regulate neural functions by communicating with other nerve cells, and these nerve cells have two main ways of communication. One is "electrical communication," which is a method of communication within nerve cells, and the other is "extracellular communication," which is a method of communication between nerve cells, called "chemical communication." Chemical communication occurs at synapses (the junction between the axon terminal of one nerve cell and the dendrite of the next nerve cell), and is a method in which neurotransmitters (= chemical substances) are secreted in the presynaptic process and transmitted to another synapse. In the postsynaptic process, neurons that receive neurotransmitters through synapses become activated and excited when the amount of neurotransmitters exceeds the threshold. The activated nerve cells generate electrical signals in the dendrites, transmit the signals to the axons, and the axons secrete neurotransmitters through the synapses, and this series of processes is repeated. It is known that neurotransmitters secreted from nerve cells are the most important factors in controlling human behavior by regulating synaptic reactions with nerve cells and ultimately controlling neural circuits.

[0004] When a neurotransmitter is secreted from a nerve cell, a specific receptor on the postsynaptic nerve cell that forms a synapse with that nerve cell binds to the neurotransmitter and activates it, but the activation of the postsynaptic nerve cell and the synapse can be regulated by receptor signaling. It is presumed that human behavior is controlled by regulating the activation of neurons and synapses by neurotransmitters, and it has been reported that mutations in genes of neurotransmitters (when the neurotransmitter is a peptide), enzymes that produce neurotransmitters, or neurotransmitter receptors are associated with behavioral control disorders. Furthermore, drugs that regulate the amount of neurotransmitters or signaling through receptors are known to control human behavior.

[0005] As mentioned above, neurotransmitters that control behavior include monovalent amines (catecholamines, serotonin, etc.), acetylcholine, excitatory or inhibitory amino acids, and various neuropeptides, and their receptors are broadly classified into ionotropic receptors, G protein-coupled receptors, and tyrosine kinase receptors.

[0006] Among the various neurotransmitters in the brain, dopamine, a catecholamine neurotransmitter, can become an excitatory signal or an inhibitory signal depending on the type of postsynaptic dopamine receptor. In our body, dopamine is related to behavior, attention, learning, motivation, reward system, reinforcement effect, etc. When dopamine activity decreases, depressive symptoms such as lethargy, loss of motivation, and loss of energy appear. Dopamine also excites nerve cells in the frontal lobe and affects mental activities such as short-term memory, planning, and strategy. In particular, the reward provided by dopamine plays a very important role in building the neural circuits of the early brain, as it causes humans to repeat actions and learning in order to obtain the pleasure of this reward.

[0007] Norepinephrine is a catecholamine neurotransmitter present in the autonomic nervous system, and is known as a secondary neurotransmitter secreted by the release of dopamine. Norepinephrine is associated with the arousal effect of making the body tense and alert to the surroundings, and is involved in fear and stress responses. In particular, norepinephrine is closely related to emotions and is thought to be the cause of mood disorders (depression, bipolar disorder, etc.). In other words, there is a hypothesis that a state in which the activity of norepinephrine and dopamine is reduced is depression, and a state in which the activity of norepinephrine is excessively promoted is mania.

[0008] Serotonin is a neurotransmitter that normally acts in an inhibitory manner and is related to many basic physiological phenomena in humans (sleep, appetite, pain, thermoregulation, cardiovascular response, sexual desire, anxiety, depression, etc.). Clinically, serotonin is thought to be involved in the causes of various neuropsychiatric disorders (depression, schizophrenia, obsessive-compulsive disorder, anxiety disorder, eating disorder, sleep disorder, sexual disorder, impulse control disorder, developmental disorder, brain degenerative disease, stress disorder, movement disorder, etc.), and its association with depression in particular is considered to be very important.

[0009] Synaptic vesicles in nerve cells contain neurotransmitters, and when a nerve cell receives a stimulus, calcium ion channels open in front of the synapse between nerve cells, allowing calcium to flow into the nerve cell and move the synaptic vesicles to the cell membrane of the nerve cell. The vesicles that have moved to the cell membrane are released into the synapse by exocytosis at the axon terminal. The released neurotransmitters interact with receptors to excite or inhibit the nerve cell that received the neurotransmitter, and the neurotransmitters that remain after acting on the receptors are either reabsorbed at the axon terminal of the presynaptic cell, degraded by degradative enzymes present in the postsynaptic membrane, or diffused to the outside and removed by glial cells.

[0010] The reuptake process is carried out by neurotransmitter transporters. Depending on the type of neurotransmitter, there are specific neurotransmitter transporters that are responsible for reuptake of neurotransmitters present in the synaptic cleft in the synaptic membrane into the presynaptic cell. Regulation of neurotransmitter concentration by this process ultimately affects the intensity and duration of activation of various receptors present in the postsynaptic neuron.

[0011] As mentioned above, neurotransmitter reuptake refers to the process in which a neurotransmitter is reabsorbed into the presynaptic cell by a specific neurotransmitter transporter in the membrane of the presynaptic cell where the neurotransmitter was released, and the neurotransmitter is inactivated. When neurotransmitter reuptake increases, neurotransmitter deficiency or imbalance occurs, leading to the development of neurotransmitter reuptake-related diseases. The treatment of these reuptake-related diseases involves increasing the concentration of neurotransmitters in the synapse by inhibiting neurotransmitter reuptake, thereby improving symptoms.

[0012] Neurotransmitter reuptake inhibitors include selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, selective norepinephrine reuptake inhibitors, dopamine-norepinephrine reuptake inhibitors, serotonin receptor antagonist-serotonin reuptake inhibitors, and the like. These inhibitors are used to treat depression, mood disorders, ADHD, chronic neuropathic pain, obsessive-compulsive disorder, panic disorder, anxiety disorder, menopausal disorders, and the like.

[0013] Drugs for treating mental disorders are continuously being developed. Among them, as a technology related to neurotransmitter reuptake inhibitors, Korean Patent Publication No. 10-2009-0089439 discloses a chromen-2-one derivative and its use as a monoamine neurotransmitter reuptake inhibitor and for treating mental disorders, and Korean Patent Publication No. 10-2009-0117736 relates to a composition for selective serotonin reuptake inhibition and a method for preparing the same, and discloses a composition containing asiaticoside and madecassoside.

[0014] However, currently available drugs for treating psychiatric disorders in the neurological field only act on one of the various neurotransmitters suggested to be the cause of the pathology, or they are not sufficiently selective for neurotransmitters, resulting in problems with therapeutic efficacy and patient compliance and causing serious side effects (growth disorders, sleep disorders, dependence, etc.). Therefore, there is a demand for the development of drugs that can flexibly regulate multiple targets with diverse selectivity for neurotransmitters.

[0015] From this perspective, development of drugs that modulate multiple targets has been promoted. Korean Patent Publication No. 10-2013-0026292, relating to novel azetidine derivatives and antidepressant compositions containing the same, discloses an antidepressant composition containing an azetidine derivative that can simultaneously inhibit the reuptake of dopamine, serotonin and norepinephrine. Korean Patent Publication No. 2002-0079730 discloses the use of aryl- and heteroaryl-substituted tetrahydroisoquinolines for inhibiting the reuptake of norepinephrine, dopamine and serotonin. Korean Patent Publication No. 10-2010019982, relating to phenyl-substituted cycloalkylamines as monoamine reuptake inhibitors, discloses phenyl-substituted cycloalkylamines that inhibit the reuptake of endogenous monoamines such as dopamine, serotonin and norepinephrine from the synaptic cleft and modulate one or more monoamine transporters.

[0016] The inventors have intensively developed drugs that can flexibly regulate multiple targets by ensuring differences in selectivity in neural function control based on substances that simultaneously regulate the dopamine, norepinephrine, and serotonin nervous systems. As a result, they have confirmed that five-membered heteroaryl derivatives containing at least one N have an inhibitory effect on the triple reuptake of serotonin, norepinephrine, and dopamine and are useful for the treatment of mental disorders, thereby completing the present invention. Summary of the Invention [Problem to be solved by the invention]

[0017] One object of the present invention is to provide N-containing 5-membered heteroaryl derivatives.

[0018] Another object of the present invention is to provide a pharmaceutical composition for use in the prevention or treatment of a mental disorder, which comprises an N-containing 5-membered heteroaryl derivative as an active ingredient.

[0019] It is yet another object of the present invention to provide a triple reuptake inhibitor of serotonin, norepinephrine and dopamine, which contains an N-containing 5-membered heteroaryl derivative as an active ingredient, for use in the prevention or treatment of mental disorders.

[0020] It is still another object of the present invention to provide a health food composition containing an N-containing 5-membered heteroaryl derivative as an active ingredient, for use in preventing or improving mental disorders. [Means for solving the problem]

[0021] To achieve the above object, one aspect of the present invention provides a compound represented by the following formula 1, a stereoisomer thereof, or a pharma- ceutically acceptable salt thereof: [ka]

[0022] In formula 1, n is an integer from 0 to 5; A 1 is O, NH, or S; A 2 is N or CH; L 1 is linear or branched C 1-5 alkylene or C(=O); R 1 teeth [ka] In the formula, A 3 is NH, O, or S, and A 4 is NH, O, or S, R a1 , R a2 , R a3 , R a4 and R a5 are independently hydrogen, halogen, hydroxy, amino, CN, linear or branched C that is unsubstituted or substituted with one or more halogens. 1-10 Alkyl, unsubstituted or substituted with one or more halogens, straight or branched C 1-10 Alkoxy, -C(=O)OR c , -C(=O)N(R c )2, or -NR c C(=O)R c or R a2 and R a3 together with the carbons to which they are attached form a 5- or 6-membered heterocycloalkenyl containing one or more O; R b1 and R b2 are independently hydrogen, halogen, CN, linear or branched C that is unsubstituted or substituted with one or more halogens. 1-10 Alkyl, unsubstituted or substituted with one or more halogens, straight or branched C 1-10 Alkoxy, -C(=O)OR c , -C(=O)N(R c )2, -NR c C(=O)R c 、 or phenoxy, or R b1 and R b2 together with the carbons to which they are attached form a 5- or 6-membered heterocycloalkenyl containing one or more O; R b3 is hydrogen, hydroxy, C 1-3 Alkyl, or C 1-3 is an alkoxy; R c are independently hydrogen, substituted or unsubstituted straight-chain or branched C 1-10alkyl, wherein the substituted alkyl is substituted with one or more substituents selected from the group consisting of halogen, amino, methylamino, and dimethylamino; R 2 teeth [ka] where R d1 , R d2 , R d3 , R d4 , R e1 , R e2 , R e3 , and R e4 are independently hydrogen, halogen, or straight-chain or branched C which is unsubstituted or substituted with one or more halogens. 1-10 Alkyl, or straight or branched C unsubstituted or substituted with one or more halogens 1-10 It is an alkoxy.

[0023] Another aspect of the present invention provides a pharmaceutical composition for use in the prevention or treatment of a mental disorder, comprising a compound represented by the above formula 1, a stereoisomer thereof, or a pharma- ceutically acceptable salt thereof as an active ingredient.

[0024] Yet another aspect of the present invention provides a triple uptake inhibitor of serotonin, norepinephrine and dopamine, comprising the compound represented by the above formula 1, a stereoisomer thereof, or a pharma- ceutically acceptable salt thereof as an active ingredient, for use in the prevention or treatment of a mental disorder.

[0025] Yet another aspect of the present invention provides a health functional food composition for use in preventing or improving a mental disorder, comprising the compound represented by the above formula 1, its stereoisomer, or a pharma- ceutically acceptable salt thereof as an active ingredient.

[0026] Yet another aspect of the present invention provides a method for use in the prevention or treatment of a mental disorder, the method comprising administering to a subject in need thereof a pharmaceutical composition or a health functional food composition containing the compound represented by the above formula 1, its stereoisomer, or its pharma- ceutically acceptable salt as an active ingredient.

[0027] Yet another aspect of the present invention provides use of a pharmaceutical composition or a health functional food composition containing the compound represented by the above formula 1, its stereoisomer, or a pharma- ceutically acceptable salt thereof as an active ingredient in the prevention or treatment of a mental disorder. Effect of the Invention

[0028] The compound represented by formula 1 according to the present invention has excellent triple reuptake inhibitory activity of serotonin, norepinephrine and dopamine, and therefore may be useful for treating mental disorders. BEST MODE FOR CARRYING OUT THEINVENTION

[0029] The present invention will be described in detail below.

[0030] Meanwhile, the embodiments of the present invention can be modified in various forms, and the scope of the present invention is not limited to the embodiments described below. Moreover, the embodiments of the present invention are provided to more completely explain the present invention to those skilled in the art. Furthermore, throughout this specification, "including" a certain component does not mean excluding other components, but may further include other components, unless otherwise specified.

[0031] One aspect of the present invention provides a compound represented by the following formula 1, a stereoisomer thereof, or a pharma- ceutically acceptable salt thereof: [ka]

[0032] In the above formula 1, n is an integer from 0 to 5; A 1is O, NH, or S; A 2 is N or CH; L 1 is linear or branched C 1-5 alkylene or C(=O); R 1 teeth [ka] In the formula, A 3 is NH, O, or S, and A 4 is NH, O, or S, R a1 , R a2 , R a3 , R a4 and R a5 are independently hydrogen, halogen, hydroxy, amino, CN, linear or branched C that is unsubstituted or substituted with one or more halogens. 1-10 Alkyl, unsubstituted or substituted with one or more halogens, straight or branched C 1-10 Alkoxy, -C(=O)OR c , -C(=O)N(R c )2, or -NR c C(=O)R c or R a2 and R a3 together with the carbons to which they are attached form a 5- or 6-membered heterocycloalkenyl containing one or more O; R b1 and R b2 are independently hydrogen, halogen, CN, linear or branched C that is unsubstituted or substituted with one or more halogens. 1-10 Alkyl, unsubstituted or substituted with one or more halogens, straight or branched C 1-10 Alkoxy, -C(=O)OR c , -C(=O)N(R c )2, -NR c C(=O)R c 、 or phenoxy, or R b1 and R b2together with the carbons to which they are attached form a 5- or 6-membered heterocycloalkenyl containing one or more O; R b3 is hydrogen, hydroxy, C 1-3 Alkyl, or C 1-3 is an alkoxy; R c are independently hydrogen, substituted or unsubstituted straight-chain or branched C 1-10 alkyl, wherein the substituted alkyl is substituted with one or more substituents selected from the group consisting of halogen, amino, methylamino, and dimethylamino; R 2 teeth [ka] where R d1 , R d2 , R d3 , R d4 , R e1 , R e2 , R e3 , and R e4 are independently hydrogen, halogen, or straight-chain or branched C which is unsubstituted or substituted with one or more halogens. 1-10 Alkyl, or straight or branched C unsubstituted or substituted with one or more halogens 1-10 It is an alkoxy. In the above formula 1, R 1 teeth [ka] In the formula, A 3 is NH, O, or S, and A 4 is NH, O, or S, R a1 , R a2 , R a3 , R a4 and R a5 are independently hydrogen, halogen, hydroxy, amino, CN, linear or branched C that is unsubstituted or substituted with one or more halogens. 1-5 Alkyl, unsubstituted or substituted with one or more halogens, straight or branched C 1-5Alkoxy, -C(=O)OR c , -C(=O)N(R c )2, or -NR c C(=O)R c or R a2 and R a3 together with the carbons to which they are attached form a 5- or 6-membered heterocycloalkenyl containing one or more O; R b1 and R b2 are independently hydrogen, halogen, CN, linear or branched C that is unsubstituted or substituted with one or more halogens. 1-5 Alkyl, unsubstituted or substituted with one or more halogens, straight or branched C 1-5 Alkoxy, -C(=O)OR c , -C(=O)N(R c )2, -NR c C(=O)R c 、 or phenoxy, or R b1 and R b2 together with the carbons to which they are attached form a 5- or 6-membered heterocycloalkenyl containing 1 or 2 O; R c are independently hydrogen, substituted or unsubstituted straight-chain or branched C 1-5 alkyl, wherein the substituted alkyl is substituted with one or more substituents selected from the group consisting of amino, methylamino, and dimethylamino; R 2 teeth [ka] where R d1 , R d2 , R d3 , R d4 , R e1 , R e2 , R e3 , and R e4 are independently hydrogen, halogen, or straight-chain or branched C which is unsubstituted or substituted with one or more halogens. 1-5Alkyl, or straight or branched C unsubstituted or substituted with one or more halogens 1-5 It is an alkoxy.

[0033] In the above formula 1, n is an integer from 0 to 2; A 1 is O, NH, or S, A 2 is N or CH, L 1 is CH2 or C(=O), R 1 teeth [ka] In the formula, A 3 is NH, O, or S, and A 4 is NH, O, or S, R a1 , R a2 , R a3 , R a4 , and R a5 are independently hydrogen, F, Cl, OH, -NH2, CN, methyl, -CF3, methoxy, -C(=O)OCH3, or -C(=O)OH; R b1 and R b2 are independently hydrogen or methoxy, or R b1 and R b2 together with the carbon to which they are attached to form 1,3-dioxoles, R 2 teeth [ka] where R d1 , R d2 , R d3 , and R d4 may be hydrogen, R e1 , R e2 , R e3 , and R e4 may independently be hydrogen, Cl or methoxy.

[0034] In the above formula 1, n is an integer of 0 or 1, A 1 is O, NH, or S, A 2 is N or CH, L 1 is CH2 or C(=O), R 1 teeth [ka] [ka] and R 2 teeth [ka] may be also possible.

[0035] Examples of compounds represented by formula 1 according to the present invention include the following compound groups: <1> 2-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-1H-indole <2> 2-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-5-fluoro-1H-indole <3> 2-(5-((4-phenylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-1H-indole <4> 2-(5-((4-benzylpiperazin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-1H-indole <5> 2-(5-((4-(3,4-dichlorobenzyl)piperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-1H-indole <6> 2-(5-((4-(4-methoxybenzyl)piperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-1H-indole <7> 2-(5-((4-(4-chlorobenzyl)piperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-1H-indole <8> 2-(5-((4-(3-chlorobenzyl)piperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-1H-indole <9> 4-Benzyl-1-((5-phenyl-4H-1,2,4-triazol-3-yl)methyl)piperidine <10> 4-Benzyl-1-((5-(4-methoxyphenyl)-4H-1,2,4-triazol-3-yl)methyl)piperidine <11> (4-benzylpiperidin-1-yl)(5-(4-methoxyphenyl)-4H-1,2,4-triazol-3-yl)methanone <12> 2-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-5,6-dimethoxy-1H-indole <13> 2-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-5-methoxy-1H-indole <14> 2-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-5-chloro-1H-indole <15> 2-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-5-methyl-1H-indole <16> 2-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-6-fluoro-1H-indole <17> 2-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-1H-indol-5-carbonitrile <18> 2-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-6-methoxy-1H-indole <19> 2-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-7-methoxy-1H-indole <20> Methyl 2-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-1H-indol-5-carboxylate <21> 4-Benzyl-1-((5-(naphthalen-2-yl)-4H-1,2,4-triazol-3-yl)methyl)piperidine <22> 3-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-1H-indole <23> 2-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-5-(trifluoromethyl)-1H-indole <24> 2-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-4-chloro-1H-indole <25> 1-((5-(benzofuran-2-yl)-4H-1,2,4-triazol-3-yl)methyl)-4-benzylpiperidine <26> 1-((5-(benzo[b]thiophen-2-yl)-4H-1,2,4-triazol-3-yl)methyl)-4-benzylpiperidine <27> 1-((5-(benzo[d][1,3]dioxol-5-yl)-4H-1,2,4-triazol-3-yl)methyl)-4-benzylpiperidine <28> 2-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-1H-indole-5-carboxylic acid <29> 2-(5-((4-(3,4-dichlorobenzyl)piperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-5-fluoro-1H-indole <30> 2-(5-((4-(3,4-dichlorobenzyl)piperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-5-methyl-1H-indole <31> 2-(5-((4-(3,4-dichlorobenzyl)piperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-5,6-dimethoxy-1H-indole <32> 2-(5-((4-(1H-indol-3-yl)piperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-5-fluoro-1H-indole <33> 2-((4-benzylpiperidin-1-yl)methyl)-5-(1H-indol-2-yl)-1,3,4-oxadiazole <34> 2-((4-(3,4-dichlorobenzyl)piperidin-1-yl)methyl)-5-(1H-indol-2-yl)-1,3,4-oxadiazole <35> 2-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-1H-indol-5,6-diol <36> 3-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-5-methoxy-1H-indole <37> 3-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-7-methoxy-1H-indole <38> 3-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-6-methyl-1H-indole <39> 3-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-5-methyl-1H-indole <40> 3-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-7-chloro-1H-indole <41> 3-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-5-chloro-1H-indole <42> Methyl 3-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-1H-indol-7-carboxylate <43> 3-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-1H-indol-5-amine <44> 3-(5-((4-(3,4-dichlorobenzyl)piperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-5-methoxy-1H-indole <45> 3-(5-((4-(3,4-dichlorobenzyl)piperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-7-methoxy-1H-indole <46> 4-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)benzonitrile <47> 4-Benzyl-1-((5-(4-fluorophenyl)-4H-1,2,4-triazol-3-yl)methyl)piperidine <48> 4-Benzyl-1-((5-(3,4-dimethoxyphenyl)-4H-1,2,4-triazol-3-yl)methyl)piperidine <49> 4-Benzyl-1-((5-(4-(trifluoromethoxy)phenyl)-4H-1,2,4-triazol-3-yl)methyl)piperidine <50> 4-Benzyl-1-((5-(4-(trifluoromethyl)phenyl)-4H-1,2,4-triazol-3-yl)methyl)piperidine <51> N-(4-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)phenyl)acetamide <52> 6-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)naphthalen-2-ol <53> 4-Benzyl-1-((5-(4-phenoxyphenyl)-4H-1,2,4-triazol-3-yl)methyl)piperidine <54> 4-Benzyl-1-((5-(3-(trifluoromethoxy)phenyl)-4H-1,2,4-triazol-3-yl)methyl)piperidine <55> 4-Benzyl-1-((5-(3-(trifluoromethyl)phenyl)-4H-1,2,4-triazol-3-yl)methyl)piperidine <56> 3-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-6-methoxy-1H-indole <57> 2-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-1H-indol-5-carboxamide <58> 4-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-N-(2-(dimethylamino)ethyl)benzamide <59> 3-(5-((4-(3,4-dichlorobenzyl)piperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-6-methoxy-1H-indole <60> Methyl 3-(5-((4-(3,4-dichlorobenzyl)piperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-1H-indole-7-carboxylate <61> 4-(3,4-Dichlorobenzyl)-1-((5-(4-(trifluoromethoxy)phenyl)-4H-1,2,4-triazol-3-yl)methyl)piperidine <62> 4-(3,4-Dichlorobenzyl)-1-((5-(4-(trifluoromethyl)phenyl)-4H-1,2,4-triazol-3-yl)methyl)piperidine <63> Methyl 2-amino-4-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)benzoate <64> 2-(5-((4-benzylpiperazin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-5-fluoro-1H-indole <65> 2-(5-((4-benzylpiperazin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-5-chloro-1H-indole <66> N-(2-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-1H-indol-5-yl)acetamide <67> 2-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-1H-indol-5-ol <68> (4-benzylpiperidin-1-yl)(5-(5-fluoro-1H-indol-2-yl)-4H-1,2,4-triazol-3-yl)methanone <69> 2-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-6-butoxy-1H-indole <70> 2-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-3-methyl-1H-indole <71> 2-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-4,6-dichloro-1H-indole <72> 2-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-5,6-dichloro-1H-indole <73> 6-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-5H-[1,3]dioxolo[4,5-f]indole <74> 7-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-2,3-dihydro-6H-[1,4]dioxino[2,3-f]indole <75> 3-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-6-fluoro-1H-indole, and <76> 6-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-1H-indole.

[0036] The compound represented by formula 1 of the present invention can be used in the form of a pharmaceutically acceptable salt, and an acid addition salt formed with a pharmaceutically acceptable free acid is useful as the salt. The acid addition salt is obtained from inorganic acids (e.g., hydrochloric acid, nitric acid, phosphoric acid, sulfuric acid, hydrobromic acid, hydroiodic acid, nitrous acid, phosphoric acid, etc.), non-toxic organic acids (e.g., aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanoic acids, hydroxyalkanoic acids and alkanedioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, etc.), organic acids (e.g., trifluoroacetic acid, acetic acid, benzoic acid, citric acid, lactic acid, maleic acid, gluconic acid, methanesulfonic acid, 4-toluenesulfonic acid, tartaric acid, fumaric acid, etc.). Such pharma- ceutically non-toxic salts include sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, nitrate, phosphate, monohydrogen phosphate, dihydrogen phosphate, metaphosphate, pyrophosphate chloride, bromide, iodide, fluoride, acetate, propionate, decanoate, caprylate, acrylate, formate, isobutyrate, caprate, heptanoate, propiolate, oxalate, malonate, sulfate, suberate, sebacate, fumarate, maleate, butyrate-1,4-dioate, hexane-1,6-dioate, benzoate, and chlorobenzoate. , methylbenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, phthalate, terephthalate, benzenesulfonate, toluenesulfonate, chlorobenzenesulfonate, xylenesulfonate, phenylacetate, phenylpropionate, phenylbutyrate, citrate, lactate, β-hydroxybutyrate, glycolate, maleate, tartrate, methanesulfonate, propanesulfonate, naphthalene 1-sulfonate, naphthalene 2-sulfonate, mandelate, and the like.

[0037] The acid addition salt according to the present invention can be prepared by a conventional method, for example, by dissolving the derivative of formula 1 in an organic solvent (e.g., methanol, ethanol, acetone, methylene chloride, acetonitrile, etc.), adding an organic acid or an inorganic acid, and filtering and drying the resulting precipitate. Alternatively, the acid addition salt can be prepared by distilling the solvent and excess acid in an organic solvent under reduced pressure, drying, and crystallizing the resulting solution.

[0038] Furthermore, a pharma- ceutically acceptable metal salt may be prepared using a base. For example, an alkali metal salt or an alkaline earth metal salt may be obtained by dissolving a compound in an excess alkali metal hydroxide solution or an alkaline earth metal hydroxide solution, filtering the undissolved compound salt, and evaporating the filtrate to dryness. In this case, it is pharma- ceutical suitable to prepare a sodium salt, a potassium salt, or a calcium salt as the metal salt. Alternatively, a corresponding salt may be obtained by reacting an alkali metal salt or an alkaline earth metal salt with a suitable negative salt (e.g., silver nitrate).

[0039] Furthermore, the present invention includes not only the compound represented by formula 1 and its pharma- ceutically acceptable salts, but also solvates, optical isomers, hydrates, etc. prepared therefrom.

[0040] "Hydrate" refers to the compound of the present invention, or a salt thereof, containing a stoichiometric or non-stoichiometric amount of water bound by non-covalent intermolecular forces. The hydrate of the compound of formula 1 of the present invention may contain stoichiometric or non-stoichiometric water bound by non-covalent intermolecular forces. The hydrate may contain 1 equivalent or more, preferably 1 to 5 equivalents of water. Such a hydrate may be prepared by crystallizing the compound of formula 1 of the present invention, its stereoisomer, or its pharma- ceutical acceptable salt from water or a water-containing solvent.

[0041] The term "solvate" refers to a compound of the present invention or a salt thereof that contains a solvent bound by non-covalent intermolecular forces, either stoichiometrically or non-stoichiometrically. Such solvents are preferably volatile, non-toxic, and / or suitable for administration to humans.

[0042] "Isomers" refer to compounds of the present invention or salts thereof that have the same chemical or molecular formula but are structurally or stereochemically different. Such isomers include structural isomers (e.g., tautomers, etc.), R or S isomers having asymmetric carbon centers, stereoisomers (e.g., geometric isomers (trans, cis)), optical isomers (enantiomers), etc. All of these isomers and mixtures thereof are included within the scope of the present invention.

[0043] The compound of formula 1 according to the present invention can be prepared as shown in Reaction 1 below: It can be prepared according to a preparation method comprising reacting a compound represented by formula 2 with a compound represented by formula 3 to prepare a compound represented by formula 1.

[0044] [Reaction 1] [ka]

[0045] In the above reaction 1 R 1 , R 2 A 1 , A 2 , L 1 and n is as defined in formula 1 above.

[0046] Specifically, the preparation method of Reaction 1 is a method of preparing a compound represented by formula 1 by dehydrating a hydroxyl of a compound represented by formula 2 with an amine of a compound represented by formula 3 under Mitsunobu conditions. The preparation method may be carried out according to the embodiment of the present invention using reaction conditions known to those skilled in the art, but this is merely an example and is not limited thereto.

[0047] Another aspect of the present invention provides a pharmaceutical composition for use in the prevention or treatment of a mental disorder, comprising a compound represented by formula 1, an optical isomer thereof, or a pharma- ceutically acceptable salt thereof as an active ingredient.

[0048] The compound can inhibit the reuptake of serotonin, norepinephrine, and dopamine.

[0049] Mental disorders include bulimia nervosa, mood disorders, depression, atypical depression, secondary depression due to pain, major depressive disorder, dysthymia, bipolar disorder, bipolar I disorder, bipolar II disorder, periodic disorder, mood disorders due to general illness, mood disorders due to substances, pseudo-dementia, Ganger syndrome, obsessive-compulsive disorder, panic disorder, panic disorder without agoraphobia, panic disorder with agoraphobia, agoraphobia without a history of panic disorder, panic attacks, memory disorders, memory loss, attention deficit hyperactivity disorder, obesity. Anxiety disorders, generalized anxiety disorder, eating disorders, Parkinson's disease, Parkinson's symptoms, dementia, age-related dementia, senile dementia, Alzheimer's disease, Down's syndrome, dementia complications of acquired immune deficiency syndrome, memory dysfunction due to aging, specific phobia, social phobia, social anxiety disorder, post-traumatic stress disorder. Acute stress disorder, chronic stress disorder, drug addiction, drug abuse, drug abuse tendency, cocaine abuse, nicotine abuse, tobacco abuse, alcoholism, alcoholism, pathological kleptomania, withdrawal syndrome due to withdrawal from addictive substances, pain, chronic pain, inflammatory pain, neuropathic pain, diabetic neuropathic pain, diabetic neuropathic pain, migraine, tension headache, chronic tension headache, depression-related pain, fibromyalgia, arthritis, osteoarthritis, rheumatoid arthritis, lower back pain, cancer pain, irritable bowel syndrome, postoperative pain, postmastectomy pain syndrome (PMPS), post-stroke pain, drug-induced neuropathy diabetic neuropathy, pain due to the sympathetic nervous system, trigeminal neuralgia, toothache, facial muscle pain, phantom limb pain, loss of appetite, The condition may be at least one selected from the group consisting of premenstrual syndrome, premenstrual dysphoric disorder, late luteal syndrome, post-traumatic syndrome, chronic fatigue syndrome, persistent vegetative state, urinary incontinence, stress urinary incontinence, urge urinary incontinence, nocturnal urinary incontinence, sexual dysfunction, premature ejaculation, erectile dysfunction, erectile dysfunction, female premature ejaculation, restless legs syndrome, periodic limb movement disorder, eating disorder, anorexia nervosa, sleep disorder, pervasive developmental disorder, autism, Asperger's disorder, Rett's disorder, childhood disintegrative disorder, learning disability, motor skill disorder, selective mutism, trichotillomania, narcolepsy, post-stroke depression, cerebral infarction, cranial nerve disorder, Tourette's syndrome, tinnitus, tic disorder, body dysmorphic disorder, oppositional defiant disorder, post-stroke disorder, and the like.

[0050] The compound represented by formula 1 according to the present invention has excellent reuptake inhibitory effects on serotonin, norepinephrine and dopamine, and is therefore useful for treating mental disorders (see Experimental Example 1 and Table 13).

[0051] In the pharmaceutical composition according to the present invention, the compound represented by the above formula 1 or a pharma- ceutically acceptable salt thereof can be administered in various oral and parenteral dosage forms at the time of clinical administration, and more preferably in a parenteral dosage form. When formulated, the pharmaceutical composition is prepared using a diluent or excipient such as a filler, extender, binder, wetting agent, disintegrant, or surfactant that is commonly used. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and such solid preparations are prepared by mixing at least one excipient, such as starch, calcium carbonate, sucrose or lactose, gelatin, etc., with one or more compounds. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid preparations for oral administration include suspensions, oral liquids, emulsions, syrups, etc., and may contain various excipients such as wetting agents, sweeteners, flavorings, and preservatives in addition to water and liquid paraffin, which are commonly used simple diluents. Preparations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, etc. For non-aqueous solutions and suspensions, propylene glycol, polyethylene glycol, vegetable oils (eg, olive oil), injectable esters (eg, ethyl oleate), and the like may be used.

[0052] The compound represented by formula 1 or a pharma- ceutically acceptable salt thereof can be administered in various oral and parenteral dosage forms during clinical administration. When formulated, the pharmaceutical composition is prepared using a diluent or excipient such as a filler, extender, binder, wetting agent, disintegrant, or surfactant that is commonly used. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and such solid preparations are prepared by mixing at least one excipient, such as starch, calcium carbonate, sucrose or lactose, gelatin, etc., with one or more compounds. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid preparations for oral administration include suspensions, oral liquids, emulsions, syrups, etc., and may contain various excipients such as wetting agents, sweeteners, flavorings, and preservatives in addition to water and liquid paraffin, which are commonly used simple diluents. Preparations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, etc. For non-aqueous solutions and suspensions, propylene glycol, polyethylene glycol, vegetable oils (eg, olive oil), injectable esters (eg, ethyl oleate), and the like may be used.

[0053] The compound represented by formula 1 or a pharma- ceutically acceptable salt thereof can be administered in various oral and parenteral dosage forms during clinical administration. When formulated, the pharmaceutical composition is prepared using a diluent or excipient such as a filler, extender, binder, wetting agent, disintegrant, or surfactant that is commonly used. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and such solid preparations are prepared by mixing at least one excipient, such as starch, calcium carbonate, sucrose or lactose, gelatin, etc., with one or more compounds. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid preparations for oral administration include suspensions, oral liquids, emulsions, syrups, etc., and may contain various excipients such as wetting agents, sweeteners, flavorings, and preservatives in addition to water and liquid paraffin, which are commonly used simple diluents. Preparations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, etc. For non-aqueous solutions and suspensions, propylene glycol, polyethylene glycol, vegetable oils (eg, olive oil), injectable esters (eg, ethyl oleate), and the like may be used.

[0054] A pharmaceutical composition containing the compound represented by formula 1 or a pharma- ceutical acceptable salt thereof as an active ingredient can be administered parenterally, and parenteral administration is carried out by subcutaneous injection, intravenous injection, intramuscular injection or intrapleural injection.

[0055] In this case, in order to prepare a dosage form for parenteral administration, the compound represented by the above formula 1 or a pharma- ceutically acceptable salt thereof may be mixed with water together with a stabilizer or buffer to prepare a solution or suspension, which may be prepared in an ampoule or vial as a unit dosage form. This composition may be sterilized and / or may contain a preservative, stabilizer, wetting agent or emulsifier, a salt for controlling osmotic pressure and / or a buffer, and other therapeutically useful substances, and may be formulated according to a conventional method such as a mixing method, a granulation method, or a coating method.

[0056] Dosage forms for oral administration include, for example, tablets, pills, hard / soft capsules, liquids, suspensions, emulsions, syrups, granules, elixirs, troches, etc., which contain diluents (e.g., lactose, glucose, sucrose, mannitol, sorbitol, cellulose, and / or glycine), lubricants (e.g., silica, talc, stearic acid and its magnesium or calcium salts, and / or polyethylene glycol) in addition to the active ingredient. Tablets may contain binders (e.g., magnesium aluminum silicate, starch paste, gelatin, methylcellulose, sodium carboxymethylcellulose, and / or polyvinylpyrrolidine), and may optionally contain disintegrants (e.g., starch, agar, alginic acid or its sodium salt) or effervescent mixtures, and / or absorbents, colorants, flavors, sweeteners, etc.

[0057] A pharmaceutical composition for use in the prevention or treatment of a mental disorder, which contains the compound represented by the above formula 1, an optical isomer thereof, or a pharma- ceutically acceptable salt thereof as an active ingredient, may be administered as a sole therapeutic agent or may be used in combination with other therapeutic agents.

[0058] Yet another aspect of the present invention provides a triple uptake inhibitor of serotonin, norepinephrine and dopamine, containing as an active ingredient a compound represented by the above formula 1, a stereoisomer thereof, or a pharma- ceutically acceptable salt thereof, for use in the prophylaxis or treatment of a mental disorder.

[0059] Yet another aspect of the present invention provides a health functional food composition for use in preventing or improving a mental disorder, comprising as an active ingredient a compound represented by the above formula 1, its stereoisomer, or a pharma- ceutically acceptable salt thereof.

[0060] Yet another aspect of the present invention provides a method for use in the prevention or treatment of a mental disorder, the method comprising administering to a subject in need thereof a pharmaceutical composition or a health functional food composition containing, as an active ingredient, the compound represented by the above formula 1, its stereoisomer, or a pharma- ceutically acceptable salt thereof.

[0061] Yet another aspect of the present invention provides use of a pharmaceutical composition or a health functional food composition containing the compound represented by the above formula 1, its stereoisomer, or a pharma- ceutically acceptable salt as an active ingredient in the prevention or treatment of a mental disorder. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0062] The present invention will now be described in detail with reference to examples and experimental examples.

[0063] However, the following examples and experimental examples are merely illustrative of the present invention, and the contents of the present invention are not limited to the following examples and experimental examples.

[0064] <Preparation Example 1> Preparation of boronic acid [Reaction 2] [ka]

[0065] In the above reaction 2 R a1 , R a2 , R a3 , R a4 , and R a5 is as defined in formula 1 above.

[0066] Step 1: Indole (1 eq) and N,N-dimethylpyridin-4-amine (DMAP) (2-4 mol%) were dissolved in DMF, and di-tert-butyl dicarbonate (Boc anhydride) (1.5 eq) was added dropwise at 0°C. The reaction was stirred at room temperature for 12 hours. After the reaction was completed, water was added dropwise thereto, and the resultant was extracted with ethyl acetate. The organic layer was washed successively with H2O and brine, dried over anhydrous Na2SO4, and the solvent was evaporated under reduced pressure to give boc-indole.

[0067] Step 2: The boc-indole (1 eq) synthesized in step 1 was dissolved in anhydrous tetrahydrofuran (THF) and triisopropylborate (1.5 eq) was added dropwise under nitrogen atmosphere. The reaction mixture was cooled to 0°C and then 2M solution of lithium diisopropylamide (LDA 2.0M solution in n-heptane / ethylbenzene / THF) (1.25 eq) was slowly added dropwise over 15 minutes. The reaction mixture was stirred at 0°C until the reaction was complete. After the reaction was complete, 1N HCl was added dropwise and the resulting product was extracted with ethyl acetate. The organic layer was washed with H2O and brine, dried over anhydrous Na2SO4, and the solvent was removed under reduced pressure. The product was then solidified with ethyl acetate and hexane to obtain the boronic acid.

[0068] Example 1: Preparation of 2-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-1H-indole [ka]

[0069] Step 1: 3-Bromo-1H-1,2,4-triazol-5-ylmethanol (1 eq) and indole-2 boronic acid pinacol ester (or indole-2 boronic acid) (1.1 eq) were added to a microwave vial and dissolved in 1,4-dioxane:water (4:1), to which catalyst Pd(dppf)Cl2-H2Cl2 (10 mol%) and K2CO3 (3 eq) were added dropwise at room temperature and stirred for 5 min. The reaction mixture was reacted in a Biotage microwave at 100 °C for 1.5 h. After the reaction was completed, the resultant was extracted with dichloromethane, the organic layer was washed successively with H2O and brine, dried over anhydrous Na2SO4, and the solvent was evaporated under reduced pressure. The reaction mixture was then separated and purified by MPLC to obtain (5-(1H-indol-2-yl)-4H-1,2,4-triazol-3-yl)methanol.

[0070] Step 2: (5-(1H-indol-2-yl)-4H-1,2,4-triazol-3-yl) (1 eq) synthesized in step 1, 4-benzylpiperidine (1.5 eq) and triphenylphosphine (1.5 eq) were dissolved in tetrahydrofuran (THF) at 0°C, and diethyl azodicarboxylate solution (DEAD) (1.5 eq) was added dropwise thereto. The reaction was stirred at room temperature under nitrogen atmosphere for 12 hours. After the reaction was completed, the solvent was distilled off under reduced pressure. The obtained product was extracted with dichloromethane, and the organic layer was washed with H2O and brine in that order, dried over anhydrous Na2SO4, and the solvent was distilled off under reduced pressure. The reaction mixture was then separated and purified by MPLC to obtain the compound of Example 1.

[0071] The compound of Example 2 was obtained in the same manner as in Example 1, except that R shown in Table 1 below was used in place of indole-2 boronic acid pinacol ester (or indole-2 boronic acid) in Step 1.

[0072] [Table 1]

[0073] In Step 2, the compounds of Examples 3 to 8 were obtained in the same manner as in Example 1, except that R shown in Table 2 below was used instead of 4-benzylpiperidine.

[0074] [Table 2]

[0075] Example 9: Preparation of 4-benzyl-1-((5-phenyl-4H-1,2,4-triazol-3-yl)methyl)piperidine [ka]

[0076] The synthesized 4-benzyl-1-((5-bromo-4H-1,2,4-triazol-3-yl)methyl)piperidine (1 eq), phenylboronic acid (1.3 eq), Na2CO3 (4 eq) and catalyst Pd(Ph3P)4 (0.5 eq) were dissolved in DME in a microwave vial and reacted in a Biotage microwave at 130 °C for 3 hours. After the reaction was completed, the resultant was extracted with dichloromethane, the organic layer was washed successively with H2O and brine, dried over anhydrous Na2SO4, and the solvent was evaporated under reduced pressure. The reaction mixture was then separated and purified by MPLC to obtain the compound of Example 9.

[0077] Example 10: Preparation of 4-benzyl-1-((5-(4-methoxyphenyl)-4H-1,2,4-triazol-3-yl)methyl)piperidine [ka]

[0078] The synthesized 4-benzyl-1-((5-bromo-4H-1,2,4-triazol-3-yl)methyl)piperidine (1 eq), 2-(4-methoxyphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaboroline (1.3 eq), Na2CO3 (5 eq), and catalyst PdCl2(dtbpf) (0.1 eq) were dissolved in 4-dioxane:water (3:1) and placed in a microwave vial, and the reaction mixture was reacted in a Biotage microwave at 130°C for 2 hours. After the reaction was completed, the resultant was extracted with dichloromethane, and the organic layer was washed successively with H2O and brine, dried over anhydrous Na2SO4, and the solvent was distilled off under reduced pressure. The reaction mixture was then separated and purified by MPLC to obtain the compound of Example 10.

[0079] Example 11: Preparation of (4-benzylpiperidin-1-yl)(5-(4-methoxyphenyl)-4H-1,2,4-triazol-3-yl)methanone [ka]

[0080] Step 1: 5-Bromo-4H-1,2,4-triazole-3-carboxylic acid (96 mg, 0.5 mmol, 1 eq) was dissolved in DMF, followed by dropwise addition of DIPEA (175 μL, 1.000 mmol, 2 eq), HATU (285 mg, 0.750 mmol, 1.5 eq) and 4-benzylpiperidine (105 μL, 0.600 mmol, 1.2 eq). The reaction was stirred at room temperature for 12 hours. After completion of the reaction, the resultant was extracted with ethyl acetate, the organic layer was washed successively with H2O and brine, dried over anhydrous Na2SO4, and the solvent was evaporated under reduced pressure. The reaction mixture was then separated and purified by MPLC to obtain (4-benzylpiperidin-1-yl)(5-bromo-4H-1,2,4-triazol-3-yl)methanone compound.

[0081] Step 2: (4-benzylpiperidin-1-yl)(5-bromo-4H-1,2,4-triazol-3-yl)methanone (1 eq) synthesized in step 1, 2-(4-methoxyphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaboroline (1.3 eq), Na2CO3 (5 eq), catalyst PdCl2(dtbpf) (0.1 eq) were dissolved in 4-dioxane in a microwave vial, and the reaction mixture was reacted in a Biotage microwave at 130°C for 2 hours. After the reaction was completed, the resultant was extracted with dichloromethane, the organic layer was washed successively with H2O and brine, dried over anhydrous Na2SO4, and the solvent was evaporated under reduced pressure. The reaction mixture was then separated and purified by MPLC to obtain the compound of Example 11.

[0082] Example 12: Preparation of 2-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-5,6-dimethoxy-1H-indole [ka]

[0083] Step 1: (5-Bromo-4H-1,2,4-triazol-3-yl)methanol (500 mg, 2.81 mmol, 1 eq), 4-benzylpiperidine (0.741 mL, 4.21 mmol, 1.5 eq) and triphenylphosphine (1.105 mg, 4.21 mmol, 1.5 eq) were dissolved in tetrahydrofuran (THF) at 0°C, and then diethyl azodicarboxylate (DEAD) solution (1.911 mL, 4.21 mmol, 1.5 eq) was added dropwise thereto. The reaction was stirred at room temperature under nitrogen atmosphere for 12 hours. After completion of the reaction, the solvent was evaporated under reduced pressure. The resulting product was extracted with dichloromethane, the organic layer was washed successively with H2O and brine, dried over anhydrous Na2SO4 and the solvent was evaporated under reduced pressure. Thereafter, the reaction mixture was separated and purified by MPLC to obtain a 4-benzyl-1-((5-bromo-4H-1,2,4-triazol-3-yl)methyl)piperidine compound.

[0084] Step 2: 4-benzyl-1-((5-bromo-4H-1,2,4-triazol-3-yl)methyl)piperidine (1 eq) synthesized in step 1, (1-(tert-butoxycarbonyl)-5,6-dimethoxy-1H-indol-2-yl)boronic acid (1.3 eq), Li2CO3 (2 eq), and catalyst Pd(Ph3P)4 (0.1 eq) were dissolved in 4-dioxane:water (3:1) in a microwave vial, and the reaction mixture was reacted in a Biotage microwave at 130 °C for 30 minutes. After the reaction was completed, the resultant was extracted with dichloromethane, and the organic layer was washed successively with H2O and brine, dried over anhydrous Na2SO4, and the solvent was evaporated under reduced pressure. The reaction mixture was then separated and purified by MPLC to obtain the compound of Example 12.

[0085] The compounds of Examples 13 to 27 were obtained in the same manner as in Example 12, except that R shown in Table 3 below was used in place of (1-(tert-butoxycarbonyl)-5,6-dimethoxy-1H-indol-2-yl)boronic acid in Step 2.

[0086] [Table 3-1] [Table 3-2]

[0087] Example 28: Preparation of 2-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-1H-indole-5-carboxylic acid [ka]

[0088] Methyl 2-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-1H-indol-5-carboxylate (1 eq) of Example 20 was dissolved in methanol, and then 4M aqueous potassium hydroxide solution (150 eq, excess amount) was added dropwise thereto and reacted at room temperature for 12 hours. After the reaction was completed, the obtained product was neutralized with 1M aqueous hydrochloric acid solution, extracted with dichloromethane, dried over anhydrous Na2SO4, and the solvent was distilled off under reduced pressure. The reaction mixture was then separated and purified by MPLC to obtain the compound of Example 28 in the form of a white solid.

[0089] Example 29: Preparation of 2-(5-((4-(3,4-dichlorobenzyl)piperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-5-fluoro-1H-indole [ka]

[0090] Step 1: 4-(3,4-dichlorobenzyl)piperidine HCl salt was dissolved in dichloromethane, and the resulting solution was washed with 6M NaOH aqueous solution and adjusted to pH 12 or higher. The organic layer was dried over anhydrous Na2SO4, and the solvent was removed under reduced pressure to obtain 4-(3,4-dichlorobenzyl)piperidine.

[0091] Step 2: (5-Bromo-4H-1,2,4-triazol-3-yl)methanol (500 mg, 2.81 mmol, 1 eq), 4-(3,4-dichlorobenzyl)piperidine (892 mg, 3.65 mmol, 1.3 eq) obtained in step 1, and triphenylphosphine (1.105 g, 4.21 mmol, 1.5 eq) were dissolved in tetrahydrofuran (THF) at 0°C, and then diethyl azodicarboxylate (DEAD) solution (1.911 mL, 4.21 mmol, 1.5 eq) was added dropwise thereto. The reaction was stirred at room temperature under nitrogen atmosphere for 12 hours. After completion of the reaction, the solvent was evaporated under reduced pressure. The resulting product was extracted with dichloromethane, and the organic layer was washed successively with H2O and brine, dried over anhydrous Na2SO4, and then the solvent was evaporated under reduced pressure. Thereafter, the reaction mixture was separated and purified by MPLC to obtain a 1-((5-bromo-4H-1,2,4-triazol-3-yl)methyl)-4-(3,4-dichlorobenzyl)piperidine compound.

[0092] Step 3: 1-((5-bromo-4H-1,2,4-triazol-3-yl)methyl)-4-(3,4-dichlorobenzyl)piperidine (1 eq) synthesized in step 1, (1-(tert-butoxycarbonyl)-5-fluoro-1H-indol-2-yl)boronic acid (1.3 eq), Li2CO3 (2 eq), catalyst Pd(Ph3P)4 (0.1 eq) were dissolved in 1,4-dioxane:water (3:1) in a microwave vial, and the reaction mixture was reacted in a Biotage microwave at 130°C for 30 minutes. After the reaction was completed, the resultant was extracted with dichloromethane, the organic layer was washed successively with H2O and brine, dried over anhydrous Na2SO4, and the solvent was evaporated under reduced pressure. The reaction mixture was then separated and purified by MPLC to obtain the compound of Example 29.

[0093] The compounds of Examples 30 and 31 were obtained in the same manner as in Example 29, using R shown in Table 4 below instead of (1-(tert-butoxycarbonyl)-5-fluoro-1H-indol-2-yl)boronic acid in Step 2.

[0094] [Table 4]

[0095] Example 32: Preparation of 2-(5-((4-(1H-indol-3-yl)piperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-5-fluoro-1H-indole [ka]

[0096] Step 1: (5-Bromo-4H-1,2,4-triazol-3-yl)methanol (100 mg, 0.562 mmol, 1 eq), 3-(piperidin-4-yl)-1H-indole (146 mg, 0.730 mmol, 1.3 eq) and triphenylphosphine (221 mg, 0.843 mmol, 1.5 eq) were dissolved in tetrahydrofuran (THF) at 0° C., and diethyl azodicarboxylate (DEAD) solution (0.367 ml, 0.843 mmol, 1.5 eq) was added dropwise thereto. The reaction was stirred at room temperature under nitrogen atmosphere for 12 hours. After completion of the reaction, the solvent was evaporated under reduced pressure. The resulting product was extracted with dichloromethane, the organic layer was washed successively with H2O and brine, dried over anhydrous Na2SO4, and then the solvent was evaporated under reduced pressure. Thereafter, the reaction mixture was separated and purified by MPLC to obtain 3-(1-((5-bromo-4H-1,2,4-triazol-3-yl)methyl)piperidin-4-yl)-1H-indole compound.

[0097] Step 2: 3-(1-((5-bromo-4H-1,2,4-triazol-3-yl)methyl)piperidin-4-yl)-1H-indole (1 eq), (1-(tert-butoxycarbonyl)-5-fluoro-1H-indol-2-yl)boronic acid (1.3 eq), Li2CO3 (2 eq), and catalyst Pd(Ph3P)4 (0.1 eq) were dissolved in 1,4-dioxane:water (3:1) in a microwave vial, and the reaction mixture was reacted in a Biotage microwave at 130°C for 30 minutes. After the reaction was completed, the resultant was extracted with dichloromethane, and the organic layer was washed successively with H2O and brine, dried over anhydrous Na2SO4, and the solvent was evaporated under reduced pressure. The reaction mixture was then separated and purified by MPLC to obtain the compound of Example 32.

[0098] Example 33: Preparation of 2-((4-benzylpiperidin-1-yl)methyl)-5-(1H-indol-2-yl)-1,3,4-oxadiazole [ka]

[0099] Step 1: 4-benzylpiperidine (0.502 mL, 2.85 mmol), ethyl 2-bromoacetate (0.475 mL, 4.28 mmol) and triethylamine (0.390 mL, 2.85 mmol) were dissolved in toluene, and the reaction was stirred at 80 °C for 12 h. After the reaction was completed, water was added dropwise. The resultant was extracted with ethyl acetate, and the organic layer was washed successively with H2O and brine, dried over anhydrous Na2SO4, and the solvent was evaporated under reduced pressure. The reaction mixture was then separated and purified by MPLC to give ethyl 2-(4-benzylpiperidin-1-yl)acetate.

[0100] Step 2: 2-(4-benzylpiperidin-1-yl)ethyl acetate (0.4 g, 1.530 mmol) synthesized in step 1 was dissolved in tetrahydrofuran (THF):water (1:1), and the reaction mixture was cooled to 0°C. Lithium hydroxide hydrate (0.071 g, 1.684 mmol) was added dropwise at 0°C, and the mixture was stirred for 30 minutes. The reaction mixture was then heated to room temperature and stirred at room temperature for 12 hours. After the reaction was completed, ethyl acetate was added dropwise to extract, and the solvent and aqueous layer were removed under reduced pressure. The obtained 2-(4-benzylpiperidin-1-yl)lithium acetate was used in the next reaction without purification.

[0101] Step 3: 1H-indol-2-carbohydrazide (0.285 mmol) and lithium 2-(4-benzylpiperidin-1-yl)acetate (0.314 mmol) were dissolved in POCl3 (2M), and the resulting mixture was stirred at 110°C for 3 hours. After the reaction was completed, ice water was added dropwise thereto, and the mixture was stirred for 10 minutes. Ethyl acetate was added dropwise thereto for extraction, and the organic layer was washed successively with H2O and brine, dried over anhydrous Na2SO4, and the solvent was distilled off under reduced pressure. The reaction mixture was then separated and purified by MPLC to obtain the compound of Example 33.

[0102] Example 34: Preparation of 2-((4-(3,4-dichlorobenzyl)piperidin-1-yl)methyl)-5-(1H-indol-2-yl)-1,3,4-oxadiazole [ka]

[0103] Step 1: 4-(3,4-dichlorobenzyl)piperidine HCl salt (0.3 g, 1.069 mmol), ethyl 2-bromoacetate (0.178 mL, 1.604 mmol) and triethylamine (0.146 mL, 1.069 mmol) were dissolved in toluene, and the reaction mixture was stirred at 80 °C for 12 h. After the reaction was completed, water was added dropwise and extracted with ethyl acetate. The organic layer was washed with H2O and brine successively, dried over anhydrous Na2SO4, and the solvent was distilled off under reduced pressure. The reaction mixture was then separated and purified by MPLC to obtain ethyl 2-(4-(3,4-dichlorobenzyl)piperidin-1-yl)acetate.

[0104] Step 2: 2-(4-(3,4-dichlorobenzyl)piperidin-1-yl)acetate (0.17 g, 0.515 mmol) synthesized in step 1 was dissolved in tetrahydrofuran (THF):water (1:1), and then the reaction mixture was cooled to 0°C. Lithium hydroxide hydrate (0.024 g, 0.566 mmol) was added dropwise at 0°C, and the mixture was stirred for 30 minutes. The reaction mixture was then heated to room temperature and stirred at room temperature for 12 hours. After the reaction was completed, ethyl acetate was added dropwise to extract, and the solvent and aqueous layer were removed under reduced pressure. The obtained 2-(4-(3,4-dichlorobenzyl)piperidin-1-yl)acetic acid was used in the next reaction without purification.

[0105] Step 3: 1H-Indole-2-carbohydrazide (0.285 mmol) and 2-(4-(-(3,4-dichlorobenzyl)piperidin-1-yl)acetic acid (0.314 mmol) were dissolved in POCl3 (2M), and the resultant was stirred at 110°C for 3 h. After the reaction was completed, ice water was added dropwise thereto, and the mixture was stirred for 10 min. Ethyl acetate was added dropwise thereto for extraction, and the organic layer was washed successively with H2O and brine, dried over anhydrous Na2SO4, and the solvent was evaporated under reduced pressure. The reaction mixture was then separated and purified by MPLC to obtain the compound of Example 34.

[0106] Example 35: Preparation of 2-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-1H-indole-5,6-diol [ka]

[0107] Step 1: (5-Bromo-4H-1,2,4-triazol-3-yl)methanol (500 mg, 2.81 mmol, 1 eq), 4-benzylpiperidine (0.741 mL, 4.21 mmol, 1.5 eq) and triphenylphosphine (1.105 mg, 4.21 mmol, 1.5 eq) were dissolved in tetrahydrofuran (THF) at 0°C, and then diethyl azodicarboxylate (DEAD) solution (1.911 mL, 4.21 mmol, 1.5 eq) was added dropwise thereto. The reaction was stirred at room temperature under nitrogen atmosphere for 12 hours. After completion of the reaction, the solvent was evaporated under reduced pressure. The resulting product was extracted with dichloromethane, the organic layer was washed successively with H2O and brine, dried over anhydrous Na2SO4 and the solvent was evaporated under reduced pressure. Thereafter, the reaction mixture was separated and purified by MPLC to obtain a 4-benzyl-1-((5-bromo-4H-1,2,4-triazol-3-yl)methyl)piperidine compound.

[0108] Step 2: 4-benzyl-1-((5-bromo-4H-1,2,4-triazol-3-yl)methyl)piperidine (1 eq) synthesized in step 1, (1-(tert-butoxycarbonyl)-5,6-dimethoxy-1H-indol-2-yl)boronic acid (1.3 eq), Li2CO3 (2 eq), catalyst Pd(Ph3P)4 (0.2 eq) were dissolved in 4-dioxane:water (3:1) in a microwave vial, and the reaction mixture was reacted in a Biotage microwave at 160 °C for 30 min. Once again, (1-(tert-butoxycarbonyl)-5,6-dimethoxy-1H-indol-2-yl)boronic acid (1.3 eq), Li2CO3 (2 eq), and catalyst Pd(Ph3P)4 (0.2 eq) were added dropwise to the reaction, and the reaction was then run at 160°C for 30 minutes in a Biotage microwave. After completion of the reaction, the product was extracted with dichloromethane, and the organic layer was washed successively with H2O and brine, dried over anhydrous Na2SO4, and the solvent was removed under reduced pressure. The reaction mixture was then separated and purified by MPLC to give 2-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-5,6-dimethoxy-1H-indole.

[0109] Step 3: 2-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-5,6-dimethoxy-1H-indole (1 eq) synthesized in step 2 was dissolved in acetic acid, and hydrogen bromide (acetic acid solution) (30 eq) was added dropwise at room temperature. The reaction mixture was refluxed and stirred for 12 hours. After the reaction was completed, the solvent was removed under reduced pressure, and the obtained product was dissolved in a mixed solvent of ethyl acetate and tetrahydrofuran (THF). A saturated aqueous solution of NaHCO3 was added dropwise, and the obtained product was extracted with DCM, and the organic layer was washed successively with H2O and brine, dried over anhydrous Na2SO4, and the solvent was distilled off under reduced pressure. Next, the obtained product was separated and purified by MPLC and Prep HPLC to obtain the compound of Example 35.

[0110] Example 36: Preparation of 3-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-5-methoxy-1H-indole [ka]

[0111] Step 1: (5-Bromo-4H-1,2,4-triazol-3-yl)methanol (500 mg, 2.81 mmol, 1 eq), 4-benzylpiperidine (0.741 mL, 4.21 mmol, 1.5 eq) and triphenylphosphine (1.105 mg, 4.21 mmol, 1.5 eq) were dissolved in tetrahydrofuran (THF) at 0°C, and then diethyl azodicarboxylate (DEAD) solution (1.911 mL, 4.21 mmol, 1.5 eq) was added dropwise thereto. The reaction was stirred at room temperature under nitrogen atmosphere for 12 hours. After completion of the reaction, the solvent was evaporated under reduced pressure. The resulting product was extracted with dichloromethane, the organic layer was washed successively with H2O and brine, dried over anhydrous Na2SO4, and the solvent was evaporated under reduced pressure. Thereafter, the reaction mixture was separated and purified by MPLC to obtain a 4-benzyl-1-((5-bromo-4H-1,2,4-triazol-3-yl)methyl)piperidine compound.

[0112] Step 2: 4-benzyl-1-((5-bromo-4H-1,2,4-triazol-3-yl)methyl)piperidine (1 eq) synthesized in step 1, tert-butyl 5-methoxy-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indol-1-carboxylate (1.3 eq), Li2CO3 (2 eq), catalyst Pd(Ph3P)4 (0.2 eq) were dissolved in 4-dioxane:water (3:1) in a microwave vial, and the reaction mixture was reacted in a Biotage microwave at 160°C for 30 minutes. After the reaction was completed, the resultant was extracted with dichloromethane, and the organic layer was washed successively with H2O and brine, dried over anhydrous Na2SO4, and the solvent was evaporated under reduced pressure. The reaction mixture was then separated and purified by MPLC and Prep HPLC to obtain the compound of Example 36.

[0113] Compounds of Examples 37 to 42 were obtained in the same manner as in Example 36, except that in Step 2, R shown in Table 5 below was used instead of tert-butyl 5-methoxy-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole-1-carboxylate.

[0114] [Table 5]

[0115] Example 43: Preparation of 3-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-1H-indol-5-amine [ka]

[0116] Step 1: The synthesized 4-benzyl-1-((5-bromo-4H-1,2,4-triazol-3-yl)methyl)piperidine (1 eq), (1-(tert-butoxycarbonyl)-5-((tert-butoxycarbonyl)amino)-1H-indol-3-yl)boronic acid (1.3 eq), Li2CO3 (2 eq), and catalyst Pd(Ph3P)4 (0.2 eq) were dissolved in 4-dioxane:water (3:1) in a microwave vial, and the reaction mixture was reacted in a Biotage microwave at 160 °C for 30 min. After the reaction was completed, the obtained material was extracted with dichloromethane, and the organic layer was washed successively with H2O and brine, dried over anhydrous Na2SO4, and the solvent was evaporated under reduced pressure. The reaction mixture was then separated and purified by MPLC and Prep HPLC to obtain tert-butyl (3-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-1H-indol-5-yl)carbamate.

[0117] Step 2: tert-butyl (3-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-1H-indol-5-yl)carbamate (1 eq) synthesized in step 1 was dissolved in DCM, and TFA (50 eq) was added dropwise thereto and reacted at room temperature for 3 hours. After the reaction was completed, it was neutralized with a supersaturated aqueous solution of sodium carbonate, and then extracted with dichloromethane. The resulting solution was dried over anhydrous Na2SO4, and the solvent was distilled off under reduced pressure. The reaction mixture was then separated and purified by Prep HPLC to obtain the compound of Example 43 in the form of a white solid.

[0118] Example 44: Preparation of 3-(5-((4-(3,4-dichlorobenzyl)piperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-5-methoxy-1H-indole [ka]

[0119] Step 1: 4-(3,4-dichlorobenzyl)piperidine hydrochloride was dissolved in dichloromethane, washed with 6M NaOH aqueous solution, and the pH of the obtained solution was adjusted to 12 or higher. The organic layer was dried over anhydrous Na2SO4, and the solvent was removed under reduced pressure to obtain 4-(3,4-dichlorobenzyl)piperidine.

[0120] Step 2: (5-Bromo-4H-1,2,4-triazol-3-yl)methanol (500 mg, 2.81 mmol, 1 eq), 4-(3,4-dichlorobenzyl)piperidine (892 mg, 3.65 mmol, 1.3 eq) obtained in step 1, and triphenylphosphine (1.105 g, 4.21 mmol, 1.5 eq) were dissolved in tetrahydrofuran (THF) at 0°C, and then diethyl azodicarboxylate (DEAD) solution (1.911 mL, 4.21 mmol, 1.5 eq) was added dropwise thereto. The reaction was stirred at room temperature under nitrogen atmosphere for 12 hours. After completion of the reaction, the solvent was evaporated under reduced pressure. The resulting product was extracted with dichloromethane, and the organic layer was washed successively with H2O and brine, dried over anhydrous Na2SO4, and the solvent was evaporated under reduced pressure. Thereafter, the reaction mixture was separated and purified by MPLC to obtain a 1-((5-bromo-4H-1,2,4-triazol-3-yl)methyl)-4-(3,4-dichlorobenzyl)piperidine compound.

[0121] Step 3: 1-((5-bromo-4H-1,2,4-triazol-3-yl)methyl)-4-(3,4-dichlorobenzyl)piperidine (1 eq) synthesized in step 1, tert-butyl 5-methoxy-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indol-1-carboxylate (1.3 eq), Li2CO3 (2 eq), catalyst Pd(Ph3P)4 (0.2 eq) were dissolved in 4-dioxane:water (3:1) in a microwave vial, and the reaction mixture was reacted in a Biotage microwave at 160 °C for 30 min. After the reaction was completed, the resultant was extracted with dichloromethane, the organic layer was washed successively with H2O and brine, dried over anhydrous Na2SO4, and the solvent was evaporated under reduced pressure. The reaction mixture was then separated and purified by MPLC and Prep HPLC to give Example 44.

[0122] The compound of Example 45 was obtained in the same manner as in Example 44, except that R shown in Table 6 below was used instead of tert-butyl 5-methoxy-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole-1-carboxylate.

[0123] [Table 6]

[0124] Example 46: Preparation of 4-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)benzonitrile [ka]

[0125] Step 1: (5-Bromo-4H-1,2,4-triazol-3-yl)methanol (500 mg, 2.81 mmol, 1 eq), 4-benzylpiperidine (0.741 mL, 4.21 mmol, 1.5 eq) and triphenylphosphine (1.105 mg, 4.21 mmol, 1.5 eq) were dissolved in tetrahydrofuran (THF) at 0°C, and then diethyl azodicarboxylate (DEAD) solution (1.911 mL, 4.21 mmol, 1.5 eq) was added dropwise thereto. The reaction was stirred at room temperature under nitrogen atmosphere for 12 hours. After completion of the reaction, the solvent was evaporated under reduced pressure. The resulting product was extracted with dichloromethane, the organic layer was washed successively with H2O and brine, dried over anhydrous Na2SO4, and the solvent was evaporated under reduced pressure. Thereafter, the reaction mixture was separated and purified by MPLC to obtain a 4-benzyl-1-((5-bromo-4H-1,2,4-triazol-3-yl)methyl)piperidine compound.

[0126] Step 2: 4-benzyl-1-((5-bromo-4H-1,2,4-triazol-3-yl)methyl)piperidine (1 eq) synthesized in step 1, 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile (1.3 eq), Li2CO3 (2 eq), catalyst Pd(Ph3P)4 (0.2 eq) were dissolved in 4-dioxane:water (3:1) in a microwave vial, and the reaction mixture was reacted in a Biotage microwave at 160 °C for 30 min. Once again, 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile (1.3 eq), Li2CO3 (2 eq), and catalyst Pd(Ph3P)4 (0.2 eq) were added dropwise to the reaction, and the reaction was then run at 160°C for 30 minutes in a Biotage microwave. After completion of the reaction, the product was extracted with dichloromethane, and the organic layer was washed successively with H2O and brine, dried over anhydrous Na2SO4, and the solvent was removed under reduced pressure. The reaction mixture was then separated and purified by MPLC to give 4-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)benzonitrile.

[0127] The compound of Example 55 was obtained in the same manner as in Example 46, except that R shown in Table 7 below was used instead of 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile in Step 2.

[0128] [Table 7]

[0129] Example 56: Preparation of 3-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-6-methoxy-1H-indole [ka]

[0130] Step 1: (5-Bromo-4H-1,2,4-triazol-3-yl)methanol (500 mg, 2.81 mmol, 1 eq), 4-benzylpiperidine (0.741 mL, 4.21 mmol, 1.5 eq) and triphenylphosphine (1.105 mg, 4.21 mmol, 1.5 eq) were dissolved in tetrahydrofuran (THF) at 0°C, and then diethyl azodicarboxylate (DEAD) solution (1.911 mL, 4.21 mmol, 1.5 eq) was added dropwise thereto. The reaction was stirred at room temperature under nitrogen atmosphere for 12 hours. After completion of the reaction, the solvent was evaporated under reduced pressure. The resulting product was extracted with dichloromethane, the organic layer was washed successively with H2O and brine, dried over anhydrous Na2SO4, and the solvent was evaporated under reduced pressure. Thereafter, the reaction mixture was separated and purified by MPLC to obtain a 4-benzyl-1-((5-bromo-4H-1,2,4-triazol-3-yl)methyl)piperidine compound.

[0131] Step 2: 4-benzyl-1-((5-bromo-4H-1,2,4-triazol-3-yl)methyl)piperidine (1 eq) synthesized in step 1, tert-butyl 6-methoxy-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indol-1-carboxylate (1.3 eq), Li2CO3 (2 eq), and catalyst Pd(Ph3P)4 (0.2 eq) were dissolved in 4-dioxane:water (3:1) in a microwave vial, and the reaction mixture was reacted in a Biotage microwave at 160 °C for 30 min. After the reaction was completed, the resultant was extracted with dichloromethane, and the organic layer was washed successively with H2O and brine, dried over anhydrous Na2SO4, and the solvent was evaporated under reduced pressure. The reaction mixture was then separated and purified by MPLC and Prep HPLC to obtain the title compound, 3-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-6-methoxy-1H-indole.

[0132] Example 57: Preparation of 2-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-1H-indole-5-carboxamide 2-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-1H-indole-5-carboxylic acid (1 eq) of Example 28 was dissolved in DMF, and then HBTU (3.5 eq), ammonium chloride (5 eq) and triethylamine (5 eq) were added dropwise thereto at 0° C. The reaction was stirred at room temperature for 12 hours. [ka]

[0133] After the reaction was completed, the product was extracted with ethyl acetate, and the organic layer was washed with a saturated aqueous solution of NaHCO3 and brine in that order, dried over anhydrous Na2SO4, and the solvent was distilled off under reduced pressure. The reaction mixture was then separated and purified by MPLC to obtain the title compound 2-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-1H-indole-5-carboxamide.

[0134] <Example 58> 4-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-N-(2-(dimethylamino)ethyl)benzamide [ka]

[0135] Step 1: 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol (500 mg, 2.272 mmol), 2-(dimethylamino)ethan-1-ol (0.296 ml, 2.95 mmol) and triphenylphosphine (775 mg, 2.95 mmol, 1.3 eq) were dissolved in tetrahydrofuran (THF) at 0°C, and diethyl azodicarboxylate (DEAD) solution (1.34 mL, 2.95 mmol, 1.3 eq) was added dropwise thereto. The reaction was stirred at room temperature under nitrogen atmosphere for 12 hours. After completion of the reaction, the solvent was evaporated under reduced pressure. The resulting product was extracted with dichloromethane, the organic layer was washed successively with H2O and brine, dried over anhydrous Na2SO4 and the solvent was evaporated under reduced pressure. The reaction mixture was then separated and purified by MPLC to obtain N,N-dimethyl-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)ethan-1-amine compound.

[0136] Step 2: (5-Bromo-4H-1,2,4-triazol-3-yl)methanol (500 mg, 2.81 mmol, 1 eq), 4-benzylpiperidine (0.741 mL, 4.21 mmol, 1.5 eq) and triphenylphosphine (1.105 mg, 4.21 mmol, 1.5 eq) were dissolved in tetrahydrofuran (THF) at 0°C, and then diethyl azodicarboxylate (DEAD) solution (1.911 mL, 4.21 mmol, 1.5 eq) was added dropwise thereto. The reaction was stirred at room temperature under nitrogen atmosphere for 12 hours. After completion of the reaction, the solvent was evaporated under reduced pressure. The resulting product was extracted with dichloromethane, the organic layer was washed successively with H2O and brine, dried over anhydrous Na2SO4 and the solvent was evaporated under reduced pressure. Thereafter, the reaction mixture was separated and purified by MPLC to obtain a 4-benzyl-1-((5-bromo-4H-1,2,4-triazol-3-yl)methyl)piperidine compound.

[0137] Step 3: 4-benzyl-1-((5-bromo-4H-1,2,4-triazol-3-yl)methyl)piperidine (1 eq) prepared in step 2, N,N-dimethyl-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaboran-2-yl)phenoxy)ethan-1-amine (1.3 eq), Li2CO3 (2 eq) prepared in step 1, and catalyst Pd(Ph3P)4 (0.2 eq) were dissolved in 4-dioxane:water (3:1) in a microwave vial, and the reaction mixture was reacted in a Biotage microwave at 160 °C for 30 min. After adding N,N-dimethyl-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)ethan-1-amine (1.3 eq), Li2CO3 (2 eq) and catalyst Pd(Ph3P)4 (0.2 eq) dropwise to the reaction mass again, the reaction mass was reacted at 160°C for 30 minutes. After the reaction was completed, the resultant was extracted with dichloromethane, the organic layer was washed successively with H2O and brine, dried over anhydrous Na2SO4, and the solvent was distilled off under reduced pressure. Then, the reaction mixture was separated and purified by MPLC and Prep HPLC to obtain the title compound 4-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-N-(2-(dimethylamino)ethyl)benzamide.

[0138] Example 59: Preparation of 3-(5-((4-(3,4-dichlorobenzyl)piperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-6-methoxy-1H-indole [ka]

[0139] Step 1: 4-(3,4-dichlorobenzyl)piperidine hydrochloride was dissolved in dichloromethane, washed with 6M NaOH aqueous solution, and the pH of the obtained solution was adjusted to 12 or higher. The organic layer was evaporated over anhydrous Na2SO4, and the solvent was removed under reduced pressure to obtain 4-(3,4-dichlorobenzyl)piperidine.

[0140] Step 2: (5-Bromo-4H-1,2,4-triazol-3-yl)methanol (500 mg, 2.81 mmol, 1 eq), 4-(3,4-dichlorobenzyl)piperidine (892 mg, 3.65 mmol, 1.3 eq) obtained in step 1, and triphenylphosphine (1.105 g, 4.21 mmol, 1.5 eq) were dissolved in tetrahydrofuran (THF), and then diethyl azodicarboxylate (DEAD) solution (1.911 mL, 4.21 mmol, 1.5 eq) was added dropwise thereto. The reaction was stirred at room temperature under nitrogen atmosphere for 12 hours. After completion of the reaction, the solvent was evaporated under reduced pressure. The resulting product was extracted with dichloromethane, and the organic layer was washed successively with H2O and brine, dried over anhydrous Na2SO4, and the solvent was evaporated under reduced pressure. Thereafter, the reaction mixture was separated and purified by MPLC to obtain a 1-((5-bromo-4H-1,2,4-triazol-3-yl)methyl)-4-(3,4-dichlorobenzyl)piperidine compound.

[0141] Step 3: 1-((5-bromo-4H-1,2,4-triazol-3-yl)methyl)-4-(3,4-dichlorobenzyl)piperidine (1 eq) synthesized in step 2, tert-butyl 6-methoxy-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indol-1-carboxylate (1.3 eq), Li2CO3 (2 eq), catalyst Pd(Ph3P)4 (0.2 eq) were dissolved in 4-dioxane:water (3:1) in a microwave vial, and the reaction mixture was reacted in a Biotage microwave at 160 °C for 30 min. After the reaction was completed, the resultant was extracted with dichloromethane, the organic layer was washed successively with H2O and brine, dried over anhydrous Na2SO4, and the solvent was evaporated under reduced pressure. The reaction mixture was then separated and purified by MPLC to obtain the title compound, 3-(5-((4-(3,4-dichlorobenzyl)piperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-6-methoxy-1H-indole.

[0142] Compounds of Examples 60 to 62 were obtained in the same manner as in Example 59, using R shown in Table 8 below instead of tert-butyl 6-methoxy-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole-1-carboxylate in Step 3.

[0143] [Table 8]

[0144] <Example 63> Preparation of methyl 2-amino-4-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)benzoate [ka]

[0145] Step 1: Methyl 2-amino-4-bromobenzoate (500 mg, 2.173 mmol), potassium acetate (427 mg, 4.35 mmol), bis(pinacolato)diboron (717 mg, 2.83 mmol) and Pd(dppf)Cl2.CH2Cl2 (266 mg, 0.326 mmol) were dissolved in 1,4-dioxane (15 mL), and the reaction mixture was degassed with nitrogen. The reaction mixture was stirred at 100 °C for 12 h. After the reaction was completed, the reaction mixture was filtered through Celite, and the organic layer was extracted with ethyl acetate. The organic layer was washed with 0.5 M aqueous hydrochloric acid and brine, dried over anhydrous Na2SO4, and the solvent was distilled off under reduced pressure. The obtained product was then separated and purified by MPLC to obtain methyl 2-amino-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate compound.

[0146] Step 2: (5-Bromo-4H-1,2,4-triazol-3-yl)methanol (500 mg, 2.81 mmol, 1 eq), 4-benzylpiperidine (0.741 mL, 4.21 mmol, 1.5 eq) and triphenylphosphine (1.105 mg, 4.21 mmol, 1.5 eq) were dissolved in tetrahydrofuran (THF) at 0°C, and then diethyl azodicarboxylate (DEAD) solution (1.911 mL, 4.21 mmol, 1.5 eq) was added dropwise thereto. The reaction was stirred at room temperature under nitrogen atmosphere for 12 hours. After completion of the reaction, the solvent was evaporated under reduced pressure. The resulting product was extracted with dichloromethane, the organic layer was washed successively with H2O and brine, dried over anhydrous Na2SO4 and the solvent was evaporated under reduced pressure. Thereafter, the reaction mixture was separated and purified by MPLC to obtain a 4-benzyl-1-((5-bromo-4H-1,2,4-triazol-3-yl)methyl)piperidine compound.

[0147] Step 3: 4-benzyl-1-((5-bromo-4H-1,2,4-triazol-3-yl)methyl)piperidine (1 eq) synthesized in step 2, methyl 2-amino-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate (1.3 eq), Li2CO3 (2 eq) synthesized in step 1, and catalyst Pd(Ph3P)4 (0.2 eq) were dissolved in 4-dioxane:water (3:1) in a microwave vial, and the reaction mixture was reacted in a Biotage microwave at 160 °C for 30 min. After the reaction was completed, the obtained material was extracted with dichloromethane, and the organic layer was washed successively with H2O and brine, dried over anhydrous Na2SO4, and the solvent was removed under reduced pressure. The reaction mixture was then separated and purified by MPLC and Prep HPLC to obtain the title compound, methyl 2-amino-4-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)benzoate.

[0148] Example 64: Preparation of 2-(5-((4-benzylpiperazin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-5-fluoro-1H-indole [ka]

[0149] Step 1: (5-Bromo-4H-1,2,4-triazol-3-yl)methanol (500 mg, 2.81 mmol, 1 eq), 1-benzylpiperazine (0.594 mg, 3.37 mmol, 1.2 eq) and triphenylphosphine (1.105 mg, 4.21 mmol, 1.5 eq) were dissolved in tetrahydrofuran (THF) at 0°C, and then diethyl azodicarboxylate (DEAD) solution (1.911 mL, 4.21 mmol, 1.5 eq) was added dropwise thereto. The reaction was stirred at room temperature under nitrogen atmosphere for 12 hours. After completion of the reaction, the solvent was evaporated under reduced pressure. The resulting product was extracted with dichloromethane, the organic layer was washed successively with H2O and brine, dried over anhydrous Na2SO4 and the solvent was evaporated under reduced pressure. Thereafter, the reaction mixture was separated and purified by MPLC to obtain a 1-benzyl-4-((5-bromo-4H-1,2,4-triazol-3-yl)methyl)piperazine compound.

[0150] Step 2: 1-benzyl-4-((5-bromo-4H-1,2,4-triazol-3-yl)methyl)piperazine (1 eq) synthesized in step 1, (1-(tert-butoxycarbonyl)-5-fluoro-1H-indol-2-yl)boronic acid (1.3 eq), Li2CO3 (2 eq), catalyst Pd(Ph3P)4 (0.2 eq) were dissolved in 4-dioxane:water (3:1) in a microwave vial, and the reaction mixture was reacted in a Biotage microwave at 160 °C for 30 min. After the reaction was completed, the resultant was extracted with dichloromethane, the organic layer was washed successively with H2O and brine, dried over anhydrous Na2SO4, and the solvent was evaporated under reduced pressure. The reaction mixture was then separated and purified by MPLC and Prep HPLC to obtain the title compound, 2-(5-((4-benzylpiperazin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-5-fluoro-1H-indole.

[0151] The compound of Example 65 was obtained in the same manner as in Example 64, except that R shown in Table 9 below was used instead of (1-(tert-butoxycarbonyl)-5-fluoro-1H-indol-2-yl)boronic acid in Step 2.

[0152] [Table 9]

[0153] Example 66: Preparation of N-(2-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-1H-indol-5-yl)acetamide [ka]

[0154] Step 1: (5-Bromo-4H-1,2,4-triazol-3-yl)methanol (500 mg, 2.81 mmol, 1 eq), 4-benzylpiperidine (0.741 mL, 4.21 mmol, 1.5 eq) and triphenylphosphine (1.105 mg, 4.21 mmol, 1.5 eq) were dissolved in tetrahydrofuran (THF) at 0°C, and then diethyl azodicarboxylate (DEAD) solution (1.911 mL, 4.21 mmol, 1.5 eq) was added dropwise thereto. The reaction was stirred at room temperature under nitrogen atmosphere for 12 hours. After completion of the reaction, the solvent was evaporated under reduced pressure. The resulting product was extracted with dichloromethane, the organic layer was washed successively with H2O and brine, dried over anhydrous Na2SO4, and the solvent was evaporated under reduced pressure. Thereafter, the reaction mixture was separated and purified by MPLC to obtain a 4-benzyl-1-((5-bromo-4H-1,2,4-triazol-3-yl)methyl)piperidine compound.

[0155] Step 2: 1-((5-bromo-4H-1,2,4-triazol-3-yl)methyl)-4-(3,4-dichlorobenzyl)piperidine (1 eq), (1-(tert-butoxycarbonyl)-5-((tert-butoxycarbonyl)amino)-1H-indol-2-yl)boronic acid (1.3 eq), Li2CO3 (2 eq), and catalyst Pd(Ph3P)4 (0.2 eq) were dissolved in 4-dioxane:water (3:1) in a microwave vial, and the reaction mixture was reacted in a Biotage microwave at 160 °C for 30 min. After the reaction was completed, the resultant was extracted with dichloromethane, and the organic layer was washed successively with H2O and brine, dried over anhydrous Na2SO4, and the solvent was evaporated under reduced pressure. The reaction mixture was then separated and purified by MPLC and Prep HPLC to obtain tert-butyl (2-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-1H-indol-5-yl)carbamate.

[0156] Step 3: tert-Butyl (2-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-1H-indol-5-yl)carbamate (1 eq) synthesized in step 2 was dissolved in DCM, and TFA (50 eq) was added dropwise thereto and reacted at room temperature for 3 hours. After completion of the reaction, the mixture was neutralized with saturated aqueous NaHCO3 solution, and the resulting solution was extracted with dichloromethane. The resulting solution was dried over anhydrous Na2SO4, and the solvent was removed under reduced pressure. 2-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-1H-indol-5-amine was obtained without further purification.

[0157] Step 4: 2-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-1H-indol-5-amine (1 eq) was dissolved in DCM, and triethylamine (1.1 eq) and acetic anhydride (1.1 eq) were added dropwise thereto and stirred at room temperature for 1.5 hours.

[0158] After the reaction was completed, the product was extracted with dichloromethane and methanol, and the organic layer was washed with H2O and brine in that order, dried over anhydrous Na2SO4, and the solvent was distilled off under reduced pressure. The reaction mixture was then separated and purified by MPLC and Prep TLC to obtain the title compound N-(2-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-1H-indol-5-yl)acetamide.

[0159] <Example 67> 2-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-1H-indol-5-ol [ka]

[0160] 2-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-5-methoxy-1H-indole (1 eq) of Example 13 was dissolved in dichloromethane, and then boron tribromide (2.5 eq) was added dropwise at 0°C. The reaction mixture was stirred at room temperature under a nitrogen atmosphere for 12 hours. After the reaction was completed, the solvent was distilled off under reduced pressure. The resulting product was extracted with dichloromethane, and the organic layer was washed successively with H2O and brine, dried over anhydrous Na2SO4, and the solvent was distilled off under reduced pressure. The reaction mixture was then separated and purified by MPLC to obtain 2-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-1H-indol-5-ol.

[0161] <Example 68> (4-benzylpiperidin-1-yl)(5-(5-fluoro-1H-indol-2-yl)-4H-1,2,4-triazol-3-yl)methanone The compound of Example 68 was obtained in the same manner as in Example 11, except that R shown in Table 10 was used instead of (1-(tert-butoxycarbonyl)-5-yl-fluoro-1H-indol-2-yl)boronic acid in Step 1.

[0162] [Table 10]

[0163] <Example 69> 2-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-6-butoxy-1H-indole [ka]

[0164] Step 1: 6-Butoxy-1H-indole-2-carboxylic acid (200 mg, 0.857 mmol, 1 eq) and dimethylformaldehyde (33 μL, 0.429 mmol, 0.5 eq) were dissolved in tetrahydrofuran (THF), and then oxalyl chloride (150 μL, 1.1715 mmol, 2 eq) was added dropwise at 0°C. The reaction was stirred at room temperature under nitrogen atmosphere for 5 hours. After the reaction was completed, the solvent was distilled off under reduced pressure to obtain 6-butoxy-1H-indole-2-carbonyl chloride compound.

[0165] Step 2: 6-butoxy-1H-indole-2-carbonyl chloride (1 eq) synthesized in step 1 was dissolved in tetrahydrofuran, and then ammonium hydroxide was added dropwise at 0°C to adjust the pH of the obtained mixture to 9-10, and the mixture was reacted at room temperature for 1 hour, and 5 mL of water was added dropwise thereto and stirred for 30 minutes. The obtained mixture was extracted with dichloromethane, and the organic layer was washed successively with H2O and brine, dried over anhydrous Na2SO4, and the solvent was distilled off under reduced pressure. The reaction mixture was then separated and purified by MPLC to obtain tert-butyl 6-butoxy-1H-indole-2-carboxamide.

[0166] Step 3: 6-butoxy-1H-indole-2-carboxamide (1 eq) synthesized in step 2 and Lawesson's reagent (1.2 eq) were dissolved in tetrahydrofuran, and the reaction mixture was stirred at 80° C. for 4 hours. After the reaction was completed, the solvent was distilled off under reduced pressure, and the obtained product was solidified with methanol to obtain 6-butoxy-1H-indole-2-carbothioamide.

[0167] Step 4: 6-butoxy-1H-indole-2-carbothioamide (1 eq) and methyl iodide (2 eq) synthesized in step 3 were dissolved in acetone, and the reaction mixture was stirred at 80°C for 4 hours. After the reaction was completed, the solvent was removed under reduced pressure, and the reaction mixture was reacted at room temperature for 1 hour, and 5 mL of water was added dropwise thereto, and the mixture was stirred for 30 minutes. The mixture was extracted with dichloromethane, and the organic layer was washed successively with H2O and brine, dried over anhydrous Na2SO4, and the solvent was distilled off under reduced pressure to obtain methyl-6-butoxy-1H-indole-2-carbimidothioate.

[0168] Step 5: Methyl-6-butoxy-1H-indole-2-carbimidothioate (1 eq), 2-(4-benzylpiperidin-1-yl)acetohydrazide (1 eq) and ammonium acetate (1.5 eq) synthesized in step 4 were dissolved in ethanol and stirred at 80°C for 6 hours. After the reaction was completed, the obtained product was extracted with dichloromethane, the organic layer was washed with H2O and brine in sequence, dried over anhydrous Na2SO4, and the solvent was distilled off under reduced pressure. The reaction mixture was then separated and purified by MPLC to obtain 2-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-6-butoxy-1H-indole.

[0169] In Step 1, R shown in Table 11 below was used instead of 6-butoxy-1H-indole-2=carboxylic acid, and the compounds of Examples 70 to 76 were obtained in the same manner as in Example 69.

[0170] [Table 11]

[0171] The compound names, NMR analysis results, and mass analysis results of Examples 1 to 76 are summarized in Table 12 below.

[0172] [Table 12-1] [Table 12-2] [Table 12-3] [Table 12-4] [Table 12-5] [Table 12-6] [Table 12-7] [Table 12-8] [Table 12-9] [Table 12-10] [Table 12-11]

[0173] <Experimental Example 1> Evaluation of triple reuptake inhibitory effect In order to evaluate the reuptake inhibitory effect of the compounds according to the examples of the present invention on serotonin, norepinephrine and dopamine, the following experiment was carried out, and the results are shown in Table 13.

[0174] To evaluate the reuptake inhibitory effect on dopamine, HEK-293 cells were transfected with dopamine transporter cDNA and seeded on a 24-well plate the next day. After removing the medium, each compound of the Examples or Comparative Examples diluted to 1 μM with uptake buffer was added to a concentration of 200 μL / well and incubated at 37°C for 15 minutes. 100 μL of uptake buffer containing 20 to 30 nM [3H]-DA was added and incubated at 37°C for 5 minutes. The reaction solution was quickly removed and washed three times with 1 mL of ice-cold uptake buffer. The obtained material was dissolved in 1% SDS (0.5 mL), and the degree of binding of radioisotope-labeled dopamine to the transporter was measured.

[0175] For norepinephrine (NE) and serotonin (5-HT), the degree of binding of radioisotope-labeled norepinephrine or serotonin to the transporter was measured in the same manner as above, except that cells transfected with NE or 5-HT transporter cDNA were used and [3H]-NE or [3H]-5-HT was used as the substrate.

[0176] In addition, when evaluating the reuptake inhibitory effect on dopamine, norepinephrine and serotonin, the same method was performed as a control without treatment with each compound of the Examples or Comparative Examples, and the binding degree of radioisotope-labeled dopamine, norepinephrine and serotonin to the transporter was measured, and the triple uptake inhibitory effect was evaluated as a relative ratio (% ratio) based on this as the standard (100%). That is, in the control group, the binding of dopamine, norepinephrine and serotonin to the transporter is not inhibited, but when the binding is inhibited by treatment with each compound of the Examples, the % ratio value decreases.

[0177] On the other hand, when comparing the % ratio values, in the case of the compounds of Examples 1, 2, 10, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, and 31, which have excellent dopamine reuptake inhibitory activity, the concentration at which the % ratio becomes 50% was calculated using a total of six concentrations, 1 nM, 5 nM, 10 nM, 50 nM, 100 nM, and 1 μM, and the IC 50 It is expressed as:

[0178] [Table 13-1] [Table 13-2] [Table 13-3]

[0179] In Table 13 above, SERT means serotonin transporter, NET means norepinephrine transporter, and DAT means dopamine transporter.

[0180] As shown in Table 13 above.

[0181] It will be appreciated that the compounds of the embodiments of the present invention are capable of inhibiting the reuptake of serotonin, norepinephrine, and dopamine.

[0182] Therefore, the compound represented by formula 1 according to the present invention has excellent triple reuptake inhibitory activity of serotonin, norepinephrine and dopamine, and therefore may be useful for treating mental disorders. [Industrial Applicability]

[0183] The compound represented by formula 1 according to the present invention has excellent triple reuptake inhibitory activity of serotonin, norepinephrine and dopamine, and therefore may be useful for treating mental disorders.

Claims

1. A compound represented by the following formula 1 [Formula 1] or a pharma- ceutically acceptable salt thereof, In the above formula 1, n is an integer from 0 to 1; A 1 is NH; A 2 is CH; L 1 is CH2 or C(=O); R 1 but [Case 2] In the formula, A 3 is NH, O, or S; R a1, R a2 , R a3 , R a4 and R a5 are independently hydrogen, halogen, hydroxy, amino, CN, linear or branched C unsubstituted or substituted with one or more halogens 1-10 Alkyl, unsubstituted or substituted with one or more halogens, straight or branched C 1-10 Alkoxy, -C(=O)OR c , -C(=O)N(R c ) 2 , or -NR c C(=O)R c or R a2 and R a3 together with the carbons to which they are attached form a 5- or 6-membered heterocycloalkenyl containing one or more O; R c is independently hydrogen, unsubstituted linear or branched C 1-10 is alkyl, and R 2 but [C3] In the formula, R e1, R e2 , R e3 , and R e4is hydrogen, halogen, or linear or branched C 1-10 is an alkoxy; A compound, a stereoisomer thereof, or a pharma- ceutically acceptable salt thereof.

2. R a1, R a2 , R a3 , R a4 and R a5 are independently hydrogen, halogen, hydroxy, amino, CN, linear or branched C unsubstituted or substituted with one or more halogens 1-5 Alkyl, unsubstituted or substituted with one or more halogens, straight or branched C 1-5 Alkoxy, -C(=O)OR c , -C(=O)N(R c ) 2 , or -NR c C(=O)R c or R a2 and R a3 together with the carbon to which they are attached form a 5- or 6-membered heterocycloalkenyl containing 1 or 2 O; R c is independently hydrogen, unsubstituted linear or branched C 1-5 is alkyl, and R e1, R e2 , R e3 , and R e4 are independently hydrogen, halogen, or linear or branched C 1-5 2. The compound of claim 1, a stereoisomer thereof or a pharma- ceutically acceptable salt thereof, which is alkoxy.

3. R a1, R a2 , R a3 , R a4 , and R a5 are independently hydrogen, halogen, OH, -NH 2 , CN, Methyl, -CF 3 , methoxy, butoxy, -OCF 3 , -C(=O)OCH 3 , -C(=O)OH, -C(=O)NH 2 , or -NHC(=O)CH 3 or R a2 and R a3 together with the carbon to which they are attached [C4] and R e1 , R e2 , R e3 , and R e4 The compound of claim 1 , its stereoisomer or a pharma- ceutically acceptable salt thereof, wherein is independently hydrogen, Cl, or methoxy.

4. R 1 but, [C5] [C6] 2. The compound of claim 1, a stereoisomer thereof, or a pharma- ceutically acceptable salt thereof,

5. R 2 but, [C7] 2. The compound of claim 1, a stereoisomer thereof, or a pharma- ceutically acceptable salt thereof,

6. The compound according to claim 1, wherein the compound represented by formula 1 is any one selected from the following compound group, a stereoisomer thereof, or a pharma- ceutically acceptable salt thereof: <1> 2-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-1H-indole <2> 2-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-5-fluoro-1H-indole <3> 2-(5-((4-phenylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-1H-indole <5> 2-(5-((4-(3,4-dichlorobenzyl)piperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-1H-indole <6> 2-(5-((4-(4-methoxybenzyl)piperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-1H-indole <7> 2-(5-((4-(4-chlorobenzyl)piperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-1H-indole <8> 2-(5-((4-(3-chlorobenzyl)piperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-1H-indole <12> 2-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-5,6-dimethoxy-1H-indole <13> 2-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-5-methoxy-1H-indole <14> 2-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-5-chloro-1H-indole <15> 2-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-5-methyl-1H-indole <16> 2-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-6-fluoro-1H-indole <17> 2-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-1H-indol-5-carbonitrile <18> 2-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-6-methoxy-1H-indole <19> 2-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-7-methoxy-1H-indole <20> Methyl 2-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-1H-indol-5-carboxylate <22> 3-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-1H-indole <23> 2-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-5-(trifluoromethyl)-1H-indole <24> 2-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-4-chloro-1H-indole <25> 1-((5-(benzofuran-2-yl)-4H-1,2,4-triazol-3-yl)methyl)-4-benzylpiperidine <26> 1-((5-(benzo[b]thiophen-2-yl)-4H-1,2,4-triazol-3-yl)methyl)-4-benzylpiperidine <28> 2-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-1H-indole-5-carboxylic acid <29> 2-(5-((4-(3,4-dichlorobenzyl)piperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-5-fluoro-1H-indole <30> 2-(5-((4-(3,4-dichlorobenzyl)piperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-5-methyl-1H-indole <31> 2-(5-((4-(3,4-dichlorobenzyl)piperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-5,6-dimethoxy-1H-indole <32> 2-(5-((4-(1H-indol-3-yl)piperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-5-fluoro-1H-indole <35> 2-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-1H-indol-5,6-diol <36> 3-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-5-methoxy-1H-indole <37> 3-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-7-methoxy-1H-indole <38> 3-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-6-methyl-1H-indole <39> 3-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-5-methyl-1H-indole <40> 3-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-7-chloro-1H-indole <41> 3-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-5-chloro-1H-indole <42> Methyl 3-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-1H-indol-7-carboxylate <43> 3-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-1H-indol-5-amine <44> 3-(5-((4-(3,4-dichlorobenzyl)piperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-5-methoxy-1H-indole <45> 3-(5-((4-(3,4-dichlorobenzyl)piperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-7-methoxy-1H-indole <56> 3-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-6-methoxy-1H-indole <57> 2-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-1H-indol-5-carboxamide <59> 3-(5-((4-(3,4-dichlorobenzyl)piperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-6-methoxy-1H-indole <60> Methyl 3-(5-((4-(3,4-dichlorobenzyl)piperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-1H-indole-7-carboxylate <66> N-(2-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-1H-indol-5-yl)acetamide <67> 2-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-1H-indol-5-ol <68> (4-benzylpiperidin-1-yl)(5-(5-fluoro-1H-indol-2-yl)-4H-1,2,4-triazol-3-yl)methanone <69> 2-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-6-butoxy-1H-indole <70> 2-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-3-methyl-1H-indole <71> 2-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-4,6-dichloro-1H-indole <72> 2-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-5,6-dichloro-1H-indole <73> 6-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-5H-[1,3]dioxolo[4,5-f]indole <74> 7-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-2,3-dihydro-6H-[1,4]dioxino[2,3-f]indole, and <75> 3-(5-((4-benzylpiperidin-1-yl)methyl)-4H-1,2,4-triazol-3-yl)-6-fluoro-1H-indole.

7. A pharmaceutical composition for use in the prevention or treatment of a mental disorder, comprising as an active ingredient the compound represented by formula 1 according to claim 1, its stereoisomer, or a pharma- ceutically acceptable salt thereof.

8. 8. The pharmaceutical composition of claim 7, wherein the compound inhibits the reuptake of serotonin, norepinephrine and dopamine.

9. The psychiatric disorder is selected from the group consisting of bulimia nervosa, mood disorder, depression, atypical depression, depression secondary to pain, major depressive disorder, dysthymic disorder, bipolar disorder, bipolar I disorder, bipolar II disorder, cyclic disorder, mood disorder due to a general medical condition, substance-induced mood disorder, pseudo-dementia, Ganger syndrome, obsessive-compulsive disorder, panic disorder, panic disorder without agoraphobia, panic disorder with agoraphobia, agoraphobia without history of panic disorder, panic attacks, memory deficit, memory loss, attention deficit hyperactivity disorder, obesity, anxiety , generalized anxiety disorder, eating disorders, Parkinson's disease, Parkinson's symptoms, dementia, senile dementia, senile dementia, Alzheimer's disease, Down's syndrome, dementia complications of acquired immune deficiency syndrome, memory dysfunction due to aging, specific phobia, social phobia, social anxiety disorder, post-traumatic stress disorder, acute stress disorder, chronic stress disorder, drug addiction, drug abuse, tendency to abuse drugs, cocaine addiction, nicotine addiction, tobacco addiction, alcohol addiction, alcoholism, pathological kleptomania, withdrawal syndrome due to withdrawal from addictive substances, pain , chronic pain, inflammatory pain, neuropathic pain, diabetic neuropathic pain, migraine, tension-type headache, chronic tension-type headache, depression-related pain, low back pain, cancer pain, irritable bowel syndrome, postoperative pain, post-mastectomy pain syndrome (PMPS), post-stroke pain, drug-induced neuropathy, diabetic neuropathy, sympathetic pain, trigeminal neuralgia, toothache, facial myalgia, phantom limb pain, anorexia, premenstrual syndrome, dysmenorrhea, late luteal syndrome, post-traumatic syndrome, chronic fatigue syndrome, persistent vegetative state, urinary incontinence, stress urinary incontinence, urge urinary incontinence, nocturnal urinary incontinence 8. The pharmaceutical composition of claim 7, wherein the condition is one or more selected from the group consisting of sexual dysfunction, premature ejaculation, erectile dysfunction, erectile dysfunction, restless legs syndrome, periodic limb movement disorder, eating disorders, anorexia nervosa, sleep disorders, pervasive developmental disorders, autism, Asperger's disorder, Rett disorder, childhood disintegrative disorder, learning disabilities, motor skill disorders, selective mutism, trichotillomania, narcolepsy, post-stroke depression, cerebral infarction, cranial nerve disorders, Tourette's syndrome, tinnitus, tic disorder, body dysmorphic disorder, oppositional defiant disorder, and post-stroke disorders.

10. A health functional food composition for use in preventing or improving a mental disorder, comprising as an active ingredient the compound represented by formula 1 according to claim 1, its stereoisomer, or a pharma- ceutical acceptable salt thereof.

Citation Information

Patent Citations

  • Certain Aminomethylphenylimidazole Derivatives: A New Class of Dopamine Receptor Subtype-Specific Ligands

    JP1998501819A

  • Triazole compounds and their use as dopamine-d ▲down3 ▼-ligands

    JP2002507999A

  • New agonist for therapy of disorder related to damaged neurotransmission

    JP2014122215A

  • Pharmaceutical compositions containing piperazine derivatives for treating as serotonin antagonist

    KR1020100119430A

  • Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives: new classes of dopamine receptor subtype specific ligands

    US20030018025A1